Relmada Therapeutics (RLMD) 10-K 11 Sep 15 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2015	Sep. 11, 2015	Dec. 31, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	RELMADA THERAPEUTICS, INC.
Entity Central Index Key	1,553,643
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Document Type	10-K
Document Period End Date	Jun. 30, 2015
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,015
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 127,028,464
Entity Common Stock, Shares Outstanding		10,814,913

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Current assets:
Cash and cash equivalents	$ 22,469,960	$ 25,564,351
Prepaid expenses	1,497,911	178,158
Total current assets	23,967,871	25,742,509
Fixed assets, net of accumulated depreciation	23,911	9,841
Other assets	400,825	12,100
Total assets	24,392,607	25,764,450
Current liabilities:
Accounts payable	835,285	746,098
Accrued expenses	482,267	382,023
Note payable	263,752	58,357
Derivative liabilities	14,001,369	25,586,933
Total current liabilities	$ 15,582,673	26,773,411
Long-term liability - accrued expense		100,000
Total liabilities	$ 15,582,673	$ 26,873,411
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, value
Common stock, $0.001 par value, 100,000,000 shares authorized, 10,778,474 and 8,058,843 shares issued and outstanding, respectively	$ 10,778	$ 8,059
Additional paid-in capital	84,921,327	54,200,960
Accumulated deficit	(76,122,243)	(55,318,647)
Total stockholders' equity (deficit)	8,809,934	(1,108,961)
Total liabilities and stockholders' equity (deficit)	24,392,607	25,764,450
Class A convertible preferred stock
Stockholders' equity (deficit):
Preferred stock, value	$ 72	$ 667

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2015	Jun. 30, 2014
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	200,000,000	200,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	10,778,474	8,058,843
Common stock, shares outstanding	10,778,474	8,058,843
Class A convertible preferred stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,500,000	3,500,000
Preferred stock, shares issued	71,672	667,462
Preferred stock, shares outstanding	71,672	667,462

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2015	Dec. 31, 2013
Operating expenses:
Research and development	$ (839,959)	$ (7,872,397)	$ (5,248,669)
General and administrative	(12,106,859)	(9,226,883)	(1,525,257)
Total operating expenses	(12,946,818)	(17,099,280)	(6,773,926)
Loss from operations	(12,946,818)	(17,099,280)	(6,773,926)
Other (expenses) income:
Loss on change in fair value of derivative liabilities	(7,954,970)	(3,710,277)	$ (12,877,675)
Interest income	1,411	10,883
Interest expense	(435,611)	(4,922)	$ (220,307)
Total other expenses	(8,389,170)	(3,704,316)	(13,097,982)
Net loss	$ (21,335,988)	$ (20,803,596)	$ (19,871,908)
Net loss per common share - basic and diluted	$ (8.65)	$ (2.09)	$ (40.90)
Weighted average number of common shares outstanding - basic and diluted	2,466,466	9,941,156	485,853

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Total	Series A Preferred stock	Class A Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning Balance at Dec. 31, 2012	$ (3,711,319)	$ 1,701		$ 481	$ 10,397,250	$ (14,110,751)
Beginning Balance, Shares at Dec. 31, 2012		1,700,701		480,477
Issuance of Series A preferred stock and warrants for cash, net of offering costs	1,484,710	$ 1,020			148,690
Issuance of Series A preferred stock and warrants for cash, net of offering costs, Shares		1,020,125
Issuance of common stock to acquire Medeor, Inc. at fair value	3,750,000			$ 500	3,749,500
Issuance of common stock to acquire Medeor, Inc. at fair value, Shares				100,000
Issuance of common stock for services	16,918			$ 11	16,907
Issuance of common stock for services, Shares				11,279
Stock-based compensation expense	382,343				$ 382,343
Net Loss	(19,871,908)					$ (19,871,908)
Ending Balance at Dec. 31, 2013	(17,949,256)	$ 13,604		$ 992	$ 16,014,840	$ (33,982,659)
Ending Balance, Shares at Dec. 31, 2013		13,604,128		991,756
Issuance of common stock, Series A warrants and Series B warrants for cash, net of offering cost	22,229,321			$ 3,433	22,225,888
Issuance of common stock, Series A warrants and Series B for cash, net of offering cost, Shares				3,432,760
Issuance of common stock for services	8,714			$ 6	8,708
Issuance of common stock for services, Shares				5,810
Stock-based compensation expense	10,319,137				10,319,137
Fair value of warrant derivative liabilities issued in units offering	(4,333,163)				(4,333,163)
Reclassification of derivative liabilities to additional paid-in capital upon Share Exchange	6,804,625				6,804,625
Conversion of Series A preferred stock, notes payable and accrued interest to common stock	960,922	$ (2,721)		$ 2,961	960,682
Conversion of Series A preferred stock, notes payable and accrued interest to common stock, Shares		(2,720,826)		2,961,055
Issuance of common stock and Class A preferred stock in connection with share exchange	2,000,000		$ 667	$ 667	1,998,666
Issuance of common stock and Class A preferred stock in connection with share exchange, Shares			667,462	667,462
Beneficial conversion feature	186,727				$ 186,727
Net Loss	(21,335,988)					$ (21,335,988)
Ending Balance at Jun. 30, 2014	(1,108,961)		$ 3,337	$ 40,294	$ 54,166,055	$ (55,318,647)
Ending Balance, Shares at Jun. 30, 2014			3,337,309	40,294,217
Issuance of common stock for services	1,180,410			$ 84	1,180,326
Issuance of common stock for services, Shares				83,333
Issuance of common stock in connection with a warrant exercises	13,423,838			$ 2,034	13,421,804
Issuance of common stock in connection with a warrant exercises, Shares				2,033,915
Stock-based compensation expense	796,952				796,952
Reclassification of derivative liabilities to additional paid-in capital for warrant exercises	15,295,841				15,295,841
Issuance of common stock resulting from warrant exercises from consultants and Series A preferred warrant holder	$ 25,450			$ 6	$ 25,444
Issuance of common stock resulting from warrant exercises from consultants and Series A preferred warrant holder, shares				6,362
Conversion of Class A preferred stock to common stock			$ (595)	$ 595
Conversion of Class A preferred stock to common stock, shares			(595,790)	595,790
Fractional shares issued				231
Net Loss	$ (20,803,596)					$ (20,803,596)
Ending Balance at Jun. 30, 2015	$ 8,809,934		$ 72	$ 10,778	$ 84,921,327	$ (76,122,243)
Ending Balance, Shares at Jun. 30, 2015			71,672	10,778,474

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2015	Dec. 31, 2013
Cash flows from operating activities
Net Loss	$ (21,335,988)	$ (20,803,596)	$ (19,871,908)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	2,330	9,256	373
Common stock issued for services	8,714	1,180,410	3,766,918
Stock-based compensation	10,319,137	$ 796,952	382,343
Amortization of debt discount	327,776		118,639
Amortization of deferred financing costs	78,724		69,546
Loss on change in fair value of derivative liabilities	7,954,970	$ 3,710,277	12,877,675
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(89,983)	(1,209,458)	160,283
Accounts payable	565,779	89,187	(57,102)
Accrued expenses	4,287	244	315,704
Net cash used in operating activities	(2,164,254)	(16,226,728)	(2,237,529)
Cash flows from investing activities
Purchase of fixed assets	(3,673)	(23,326)	(8,871)
Net cash used in investing activities	$ (3,673)	$ (23,326)	(8,871)
Cash flows from financing activities
Proceeds from sale of Series A preferred stock and warrants			$ 3,494,428
Proceeds from sale of common stock and warrants, net of fees	$ 22,229,321
Proceeds from sale of common and Class A Series A preferred stock, pursuant to Share Exchange	$ 2,000,000
Proceeds from exercise of A warrants, net of fees		$ 13,423,838
Proceeds from warrant exercises from consultants and Series A preferred stock warrant holder		25,450
Payment of notes payable	$ (19,493)	$ (293,625)
Proceeds from subordinated promissory notes payable, net of financing costs			$ 501,600
Net cash provided by financing activities	$ 24,209,828	$ 13,155,663	3,996,028
Net (decrease) increase in cash	22,041,901	(3,094,391)	1,749,628
Cash at beginning of the period	3,522,450	25,564,351	1,772,822
Cash at end of the period	$ 25,564,351	$ 22,469,960	$ 3,522,450
Cash paid during the period for:
Income taxes
Interest	$ 1,103	$ 4,922
Non-cash investing and financing transactions:
Conversion of Series A preferred stock and subordinated notes to common stock	900,000
Conversion of accrued interest to common stock	60,922
Note payable issued in connection with director and officer insurance policies	$ 77,850	$ 557,377
Cancellation of note payable in connection with director and officer insurance policy		55,220
Reclassification of derivative liabilities to additional paid-in capital for warrant exercises		$ 15,295,841
Fair value of derivative reclassified to additional paid-in-capital in connection with Share Exchange	$ 6,804,625
Conversion of Class A preferred stock to common stock		$ 595
Fair value of derivative warrants issued with units offering	$ 4,333,163
Beneficial conversion feature	$ 186,727
Fair value of derivatives issued in connection with issuance of preferred stock			$ 1,761,063
Fair value of derivative warrants issued to lenders in connection with issuance of subordinated promissory notes			83,363
Fair value of warrants issued in connection with deferred financing costs			41,681
Fair value of derivative warrants issued for offering costs in connection with the issuance of Series A preferred stock			$ 248,655

Business

Business	12 Months Ended
	Jun. 30, 2015
Business [Abstract]
BUSINESS	NOTE 1 - BUSINESS Relmada Therapeutics, Inc. (“Relmada” or the “Company”) (a Nevada corporation), is a clinical-stage, publicly traded biopharmaceutical company developing novel versions of proven drug products together with new molecules that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of development including LevoCap ER, its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; d-Methadone, its N-methyl-D-aspartate (“NMDA”) receptor antagonist for neuropathic pain; BuTab, its oral dosage form of the opioid analgesic buprenorphine; and MepiGel, its orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. (“RTI”) which was previously a private company commenced operations in May 2004. In May 2014, RTI completed a Share Exchange with Camp Nine, Inc., a publicly traded Nevada corporation that was formed in May 2012. In July 2014, we changed the name of Camp Nine, Inc. to Relmada Therapeutics, Inc. At the Share Exchange, RTI shareholders exchanged 10 shares of RTI common stock for one share of our common stock. As a result of the Share Exchange, RTI’s shareholders acquired the majority of the Company’s issued and outstanding capital stock and RTI became the Company’s subsidiary. The Share Exchange was accounted for as a “reverse merger" rather than a business combination, wherein Relmada is considered the acquirer for accounting and financial reporting purposes. The statement of operations reflects the activities of RTI from the commencement of its operations since inception. Unless the context suggests otherwise, when we refer in this Report to business and financial information for periods prior to the consummation of the Share Exchange, we are referring to the business and financial information of RTI. During the six months ended June 30, 2014, we changed our year end to June 30 and increased its authorized common stock to 500,000,000 shares and its authorized preferred stock to 200,000,000 shares of which 3,500,000 was designated for Class A preferred stock. On August 12, 2015, the Company completed a one-for-five reverse stock reducing the authorized common share to 100,000,000 common shares. The consolidated financial statements reflects a retroactive adjustment for the reverse stock split. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable. The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with the FDA and other governmental regulations and approval requirements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2015
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The consolidated financial statements include the Company’s accounts and those of the Company’s wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are the valuation of derivative liabilities, stock-based compensation expenses and income taxes and its associated valuation allowance. Cash and Cash Equivalents The Company considers cash deposits and all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company's cash deposits are held at two high-credit-quality financial institutions. The Company's cash deposits at these institutions exceed federally insured limits. Patents Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain. Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Fixed assets are comprised of computers and software. Depreciation is calculated using the straight-line method over the estimated useful life of the related assets, which is three years. Derivatives All derivatives are recorded at fair value on the balance sheet. The Company has determined fair values using market based pricing models incorporating readily prices and or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity) that requires judgment and estimates. Fair Value of Financial Instruments The Company’s financial instruments primarily include cash, derivative liabilities and accounts payable. Due to the short-term nature of cash, accounts payable and note payable, the carrying amounts of these assets and liabilities approximate their fair value. Derivatives are recorded at fair value at each period end. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows: Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means. Level 3 Inputs - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity). Fair Value on a Recurring Basis As required by Accounting Standard Codification (“ASC”) Topic No. 820 - 10 Fair Value Measurement The following table sets forth, by level within the fair value hierarchy, the Company’s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2015: Quoted Prices In Active Significant Total Markets for Other Significant Carrying Identical Observable Unobservable Value as of Assets Inputs Inputs June 30, Description (Level 1) (Level 2) (Level 3) 2015 Derivative liabilities - warrant instruments $ - $ - $ 14,001,369 $ 14,001,369 The following table sets forth, by level within the fair value hierarchy, the Company’s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2014: Description Quoted Prices Significant Significant Unobservable Inputs Total Carrying Value as of June 30, Derivative liabilities - warrant instruments $ - $ - $ 25,586,933 $ 25,586,933 The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as level 3 in the fair value hierarchy: Significant Unobservable Inputs Year Six Months Year 2015 2014 2013 Beginning balance $ 25,586,933 $ 20,103,425 $ 5,090,988 Change in fair value of derivative liabilities included in net loss for the year ended June 30, 2015, for the six months ended June 30, 2014, and for the year ended December 31, 2013, respectively 3,710,277 7,954,970 12,877,675 Additions - warrant instruments - 4,333,163 373,699 Transfer of warrant instruments to additional paid-in-capital (15,295,841 ) (6,804,625 ) - Additions - conversion feature of Series A preferred stock - - 1,761,063 Ending balance $ 14,001,369 $ 25,586,933 $ 20,103,425 Income Taxes The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is uncertain. At June 30, 2015 and 2014, the Company had recorded a valuation allowance to the full extent of the Company’s net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold. The Company files a U.S. Federal income tax return and various state returns. Uncertain tax positions taken on our tax returns will be accounted for as liabilities for unrecognized tax benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at June 30, 2015 and 2014. The open tax years, subject to potential examination by the applicable taxing authority, for the Company are from 2012 through 2014. Research and Development Research and development costs primarily consist of research contracts for the advancement of product development, salaries and benefits, stock-based compensation, and consultants. The Company expenses all research and development costs in the period incurred. The Company makes an estimate of costs in relation to clinical study contracts. The Company analyzes the progress of studies, including the progress of clinical studies and phases, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Stock-Based Compensation The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics of those instruments. Compensation expense for warrants granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured, and is recognized over the service period. The expense is subsequently adjusted to fair value at the end of each reporting period until such warrants vest, and the fair value of such instruments, as adjusted, is expensed over the related vesting period. Adjustments to fair value at each reporting date may result in income or expense, depending upon the estimate of fair value and the amount of expense recorded prior to the adjustment. The Company reviews its agreements and the future performance obligation with respect to the unvested warrants for its vendors or consultants. When appropriate, the Company will expense the unvested warrants at the time when management deems the service obligation for future services has ceased. Net Loss per Common Share Basic net loss per common share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per common share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of Class A convertible preferred stock, Series A preferred stock, restricted stock awards, options and warrants to purchase common stock. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. Potentially dilutive securities are not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): Year Ended Six Months Year Ended December 31, Class A convertible preferred stock 71,672 667,462 - Series A preferred stock - - 2,720,826 Common stock warrants 5,362,183 8,628,911 1,785,303 Restricted stock awards 94,000 - - Common stock options 777,630 673,034 373,082 Total 6,305,485 9,969,407 4,879,211 Recent Accounting Pronouncements In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2014-12, Compensation—Stock Compensation. The amendments in this update apply to reporting entities that grant their employees stock-based payments in which the terms of the award provide that a performance target can be achieved after the requisite service period. The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, and early adoption is permitted. The Company is currently evaluating the effects of ASU 2014-12 on the consolidated financial statements. In August 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-15, Presentation of Financial Statements- Going Concern. The Update provides U.S. GAAP guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in this update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently evaluating the effects of ASU 2014-15 on the consolidated financial statements. The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of consolidated operations, consolidated financial position, or consolidated cash flows of the Company. Subsequent Events The Company’s management reviewed all material events through the date the financial statements were issued for subsequent event disclosure consideration.

Prepaid Expenses

Prepaid Expenses	12 Months Ended
	Jun. 30, 2015
Prepaid Expenses [Abstract]
PREPAID EXPENSES	NOTE 3 – PREPAID EXPENSES Prepaid expenses consisted of the following (rounded to nearest $00): June 30, June 30, Rent $ 450,700 $ 11,400 Research and development 565,100 - Insurance 337,100 77,600 Taxes 82,000 - Other 63,000 89,200 Total $ 1,497,900 $ 178,200

Notes Payable

Notes Payable	12 Months Ended
	Jun. 30, 2015
Notes Payable [Abstract]
NOTES PAYABLE	NOTE 4 - NOTES PAYABLE In May 2014, the Company entered into a note for approximately $77,850 to finance its director and officer insurance policy. At June 30, 2014, the Company owed approximately $58,400 in connection with this note payable and the interest rate was 3.4% per annum. This policy was cancelled and replaced in July 2014, whereby the Company financed another director and officer insurance policy and entered into a note for approximately $293,200. This note was fully paid during the year and it had an interest rate of 3.0% per annum. In June 2015, the Company entered into a note for approximately $263,800 and renewed its director and officer insurance policy. The interest rate is 2.8% per annum. At June 30, 2015, the note payable balance outstanding was approximately $263,800.

Derivative Liabilities

Derivative Liabilities	12 Months Ended
	Jun. 30, 2015
Derivative Liabilities [Abstract]
DERIVATIVE LIABILITIES	NOTE 5 - DERIVATIVE LIABILITIES ASC Topic No. 815 - Derivatives and Hedging The following is a summary of the assumptions used in the valuation model at June 30, 2015 and 2014: June 30, June 30, 2015 2014 Common stock issuable upon exercise of warrants 2,574,570 6,007,330 Market value of common stock on measurement date (1) $ 10.15 $ 10.00 Exercise price $ 7.50 and 11.25 $ 7.50 and 11.25 Risk free interest rate (2) 1.6 % 1.6 % Expected life in years 3.9 0.3 and 4.9 Expected volatility (3) 70 % 71% and 73 % Expected dividend yields (4) None None (1) Quoted market value of the common stock, reflects a one-for-five reverse stock split. (2) The risk-free interest rate was determined by management using the applicable Treasury Bill interest rate as of the measurement date, when applicable. (3) The historical trading volatility was determined by calculating the volatility of the Company’s peer group. (4) The Company does not expect to pay a dividend in the foreseeable future. During the year ended June 30, 2015, 2,033,915 A warrants were exercised and 1,398,845 A warrants expired, see Note 2, Fair Value on a Recurring Basis. The following were the summary of the assumptions at the transactions dates for the warrant exercises during the year ended June 30, 2015. Common stock issuable upon exercise of warrants 2,033,915 Market value of common stock on measurement date $ 15.00 Exercise price $ 7.50 Risk free interest rate 0.02 % Expected life in years 0.0 Expected volatility 71.2 % Expected dividend yields None The following table sets forth, by level within the fair value hierarchy, the Company’s derivative liabilities that were accounted for at fair value on a recurring basis as of June 30, 2015: Balance at Initial valuation of derivative Increase (decrease) in fair value of derivative Fair value of derivatives Balance at 2014 period liabilities capital 2015 Series A warrants issued in May and June 2014 offering $ 10,040,822 $ - $ 5,255,019 $ (15,295,841 ) $ - Series B warrants issued in connection with May and June 2014 offering 9,894,930 - (1,124,230 ) - 8,770,700 Placement Agent warrants issued in connection with May and June 2014 offering 5,651,181 - (420,512 ) - 5,230,669 Total $ 25,586,933 $ - $ (3,710,277 ) $ (15,295,841 ) $ 14,001,369 The following table sets forth, by level within the fair value hierarchy, the Company’s derivative liabilities that were accounted for at fair value on a recurring basis as June 30, 2014: Balance at December 31, Initial valuation of derivative Increase (decrease) in fair value of derivative Fair value of derivatives Balance at 2013 period liabilities capital 2014 Convertible preferred derivative liability issued in connection with Series A preferred stock offering $ 11,762,115 $ - $ (7,214,804 ) $ (4,547,311 ) $ - Convertible preferred derivative liability issued to Wonpung for services 2,030,589 - (1,370,262 ) (660,327 ) - Convertible preferred derivative liability issued to lenders in connection with exchange of debt for Series A preferred stock 2,219,854 - (1,262,858 ) (956,996 ) - Warrants issued in connection with Series A preferred stock offering 2,424,167 - (1,945,669 ) (478,498 ) - Warrants issued as offering costs to placement agent 1,217,083 - (1,109,421 ) (107,662 ) - Warrants issued to lenders in connection with subordinated promissory notes offering 313,258 - (259,427 ) (53,831 ) - Warrants issued to placement agent in connection with subordinated promissory notes offering 136,359 - (136,359 ) - - A warrants issued in May and June 2014 offering - 842,370 9,198,452 - 10,040,822 B warrants issued in connection with May and June 2014 offering - 2,494,655 7,400,275 - 9,894,930 Placement Agent warrants issued in connection with May and June 2014 offering - 996,138 4,655,043 - 5,651,181 Total $ 20,103,425 $ 4,333,163 $ 7,954,970 $ (6,804,625 ) $ 25,586,933 The following table sets forth, by level within the fair value hierarchy, the Company’s derivative liabilities that were accounted for at fair value on a recurring basis as of December 31, 2013: Balance at Initial valuation of derivative liabilities upon issuance of new warrants Increase in fair value of Balance at December 31, during derivative December 31, 2012 the period liabilities 2013 Convertible preferred derivative liability issued in connection with Series A preferred stock offering $ 2,492,166 $ 1,647,910 $ 7,622,039 $ 11,762,115 Convertible preferred derivative liability issued to Wonpung for services 880,214 - 1,150,375 2,030,589 Convertible preferred derivative liability issued to lenders in connection with exchange of debt for Series A preferred stock 958,861 - 1,260,993 2,219,854 Warrants issued in connection with Series A preferred stock offering 475,000 113,153 1,836,014 2,424,167 Warrants issued as offering costs to placement agent 242,500 248,655 725,928 1,217,083 Warrants issued to lenders in connection with subordinated promissory notes offering 29,158 83,363 200,737 313,258 Warrants issued to placement agent in connection with subordinated promissory notes offering 13,089 41,681 81,589 136,359 Total $ 5,090,988 $ 2,134,762 $ 12,877,675 $ 20,103,425

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Jun. 30, 2015
Stockholders' Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 6 - STOCKHOLDERS’ EQUITY Series A Preferred Stock During 2013, in a series of closings, the Company issued investors 1,020,125 shares of Series A preferred stock and 255,031 warrants to purchase shares of common stock at an exercise price of $4.00 per share with an expiration date of seven years, for gross proceeds of approximately $4,080,500 ($3,494,428 net of offering costs). In addition, the Company issued the placement agent 127,516 warrants to purchase common stock with an exercise price of $4.00 per share. Both the warrants and the Series A preferred stock contained anti-dilution features deemed to be derivatives, see Note 5. The table below reflects the gross proceeds received in connection with the 2013 offerings allocated to components of stockholders’ equity (deficit) and to derivative liabilities based upon fair value: Par value of Series A preferred stock issued $ 1,020 Additional paid-in-capital 1,483,690 Derivative warrant liabilities 113,153 Derivative preferred stock conversion feature 1,647,910 Derivative warrants issued to placement agent as offering costs 248,655 Offering costs paid-in cash 586,072 Total $ 4,080,500 Each share of Series A preferred stock automatically converted into common stock on a one-for-one basis upon the Share Exchange. There were 2,720,826 shares that were converted to common stock in May 2014. In addition, the conversion price was subject to adjustment upon a future down round if any future stock offerings are issued below $4.00 per share. This anti-dilution feature for the Series A preferred stock and for the warrants, made these instruments a derivative liability. The anti-dilution feature was terminated upon the Share Exchange and the corresponding derivative liabilities were transferred to additional paid-in capital. Class A Convertible Preferred Stock (“Class A Stock”) On May 20, 2014, the Company' subsidiary completed a Share Exchange with the Company, whereby the Company acquired 94.6% of the issued and outstanding capital stock of the subsidiary’s stockholders in exchange (“Share Exchange”) for the issuance of 5,658,215 shares of common stock to the Company’s stockholders, which represented 80.9% of Relmada’s issued and outstanding common stock after the consummation of the Share Exchange. In addition, the outstanding options and warrants were exchanged for options and warrants to purchase shares of common stock of the Company at a ratio of 10 to 1. Prior to the Share Exchange, the Company had no other assets or liabilities. The principal shareholders of the Company contributed $2 million in cash for 667,462 shares of the Company’s common stock and 667,462 shares of Class A Stock. The Class A Stock has dividend rights to two times the amount of any dividend granted by the Board of Directors of the Company to the holders of common stock. In the event of any dissolution, liquidation or winding up of the Company, whether voluntary or involuntary, the holders of Class A Stock shall be entitled to participate in any distribution out of the assets of the Corporation on an equal basis per share with the holders of the Company’s common stock. The holders of Class A Stock shall have no right to vote on any matter submitted to a vote of the holders of the Company’s common stock, including the election of directors. The Class A Stock is automatically converted on a monthly basis into common stock on a one-for-one basis by action of the Corporation, in the event the total of all shares of common stock and Class A Stock held by the shareholder do not exceed 9.9% of the issued and outstanding shares of common stock of the Company. In no event can Class A Stock be converted into common stock of the Corporation if such conversion would cause the holder to own, beneficially or otherwise, more than 9.9% of the Company’s stock. During the year ended June 30, 2015, 595,790 Class A Stock were converted to common stock. Common Stock Common stock issued in merger During 2012, an executive was granted 30,760 shares of common stock. The grant date fair value of the common stock was $1.50 per share (based on a third party valuation), or approximately $46,100 in total. The vesting schedule provided that approximately 13,670 shares vested on July 10, 2012, 11,278 shares vested on July 10, 2013 and 5,812 shares vested on January 10, 2014. As a result, the Company recorded stock-based compensation expense of approximately $8,700 and $16,900 for the six months ended June 30, 2014 and for the year ended December 31, 2013, respectively, in connection with this agreement. Common stock issued for cash On May 12, May 15 and June 10, 2014, the Company completed a private placement for the sale of units for gross proceeds of approximately $25,745,700. The units consisted of 3,432,760 shares of the Company’s common stock, A warrants to purchase 3,432,760 shares of common stock at an exercise price of $7.50 per share and B warrants to purchase 1,716,379 shares of common stock, at a exercise price of $11.25 per share. The A warrants were exercisable through October 10, 2014 and the B warrants are exercisable immediately up to a period of five years from the date of issuance. The Company may call the B warrants for redemption upon written notice to all investors of the May and June 2014 units (“investors”) at any time if the closing price of the common stock exceeds $18.75 per share for twenty consecutive trading days provided that there is an effective registration statement. Sixty business days following the date the redemption notice (“Exercise Period”) is sent to the investors, each may choose to exercise their B warrants or a portion of their B warrants, by paying the exercise price of $11.25 per share. Any warrants not exercised on the last day of the Exercise Period, will be redeemed by the Company at $0.001 per share. The Placement Agent shall receive a warrant solicitation fee equal to five % of the aggregate exercise price paid by the B warrant holders upon such exercise, following a call for redemption by the Company. The Company shall direct the B warrant holder to make such solicitation fee payment directly to the Placement Agent and the B warrant holder shall comply with such direction. The Company issued warrants to purchase 858,190 shares of common stock at $7.50 to its Placement Agent (“Agent Warrants”). The Agent Warrants are immediately exercisable and expire five years from the date of issuance. The Company paid approximately $3,516,000 including expenses to the Placement Agent and the net proceeds were approximately $22,229,300. All the warrants in this transaction have an anti-dilution provision and shall terminate upon an up-listing of the Company to a national securities exchange such as NYSE or NASDAQ. A registration rights agreement was entered into in connection with the private placement that required the Company to file a registration statement for the resale of shares of common stock and common stock issuable upon the exercise of the A warrants and B warrants. The Company was required to use commercially reasonable efforts to have the registration statement declared effective within 45 days from the filing date. If the SEC reviewed the registration statement, the Company had 180 days to have the registration statement declared effective. If the registration statement was not filed on time or declared effective within the pre-requisite time frame, the penalty was one percent of the purchase price with a maximum penalty of six percent (6%). The Securities and Exchange Commission declared the registration effective on December 30, 2014. The table below reflects the gross proceeds received in connection with the May and June 2014 offerings allocated to components of stockholders’ equity (deficit) and to derivative liabilities based upon fair value: Par value of common stock issued $ 3,433 Additional paid-in-capital 17,892,725 Derivative warrant liabilities 3,337,025 Derivative warrants issued to placement agent as offering costs 996,138 Net proceeds 22,229,321 Offering costs paid-in cash 3,516,378 Gross proceeds $ 25,745,699 Common stock issued for services For the year ended June 30, 2015, the Company issued 83,333 shares of common stock for consulting services that had a fair market of approximately $1,180,400 which was based upon the stock price at each issuance date. The Company recorded the stock-based compensation expense value to general and administrative expense. The Company is obligated to issue 16,667 shares of common stock divided equally over two quarterly installments commencing in September 2015 for consulting services. The Company will record these share issuances at the applicable fair value of the common stock on the date of issuance. Common stock issued in connection with exercise of warrants During the year ended June 30, 2015, shareholders from the May and June 2014 equity offerings exercised Series A warrants to purchase 2,033,915 shares of common stock at an exercise price of $7.50 per share that resulted in net proceeds of approximately $13,423,800 to the Company, net of approximately $1,830,500 of offering costs. During the year ended June 30, 2015, three consultants exercised their warrants and also a Series A preferred warrant holder exercised warrants aggregating 6,512 shares of common stock. The Company received approximately $25,500. Options and warrants In December 2014, the Board of Directors adopted and the shareholders approved Relmada’s 2014 Stock Option and Equity Incentive Plan, as amended (the “Plan”), which allows for the granting of common stock awards, stock appreciation rights, and incentive and nonqualified stock options to purchase shares of the Company’s common stock to designated employees, non-employee directors, and consultants and advisors. The Plan allows for the granting of 1,611,769 options or stock awards. In August 2015, the board approved an amendment to the Plan. Among other things, the Plan Amendment updates the definition of “change of control” and provides for accelerated vesting of all awards granted under the plan in the event of a change of control of the Company. At June 30, 2015, no stock appreciation rights have been issued. Stock options are exercisable generally for a period of 10 years from the date of grant and generally vest over four years. As of June 30, 2015, 740,138 shares were available for future grants under the Plan. The Company utilizes the Black-Scholes option pricing model to estimate the fair value of stock options and warrants. The price of common stock prior to the Company being public was determined from a third party valuation. The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the expected term of the equity instruments. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future. The expected volatility was based upon its peer group. The Company routinely reviews its calculation of volatility changes in future volatility, the Company’s life cycle, its peer group, and other factors. The Company uses the simplified method for share-based compensation to estimate the expected term for employee option awards for share-based compensation in its option-pricing model. The Company uses the contractual term for non-employee options to estimate the expected term, for share-based compensation in its option-pricing model. Stock-based compensation - options The Company granted an officer options to purchase 133,150 shares of its common stock in September 2013. The option has a ten-year term and an exercise price of $4.00 per share. 25% of each of the options vest immediately and the remaining 75% of the options vest in equal quarterly increments over a four-year period. The fair value of the option at the grant date was $2.70 per share using the Black-Scholes Option pricing model. During December 2013 and February 2014, the Company granted two officers options to purchase 66,840 and 200,755 (150,566, were forfeited as of June 30, 2015) shares of common stock, respectively. The options have a 10 year term and an exercise price of $4.00 and $7.50 per share, respectively. 25% of the options vest on the one year anniversary of the grant date and the remaining options vest quarterly over the following 3 years. The fair value of the options at the grant date during December 2013 and January 2014 was $2.71 per share and $4.65 per share, respectively. During November 2013, the Company an employee options to purchase 37,500 shares of common stock. The options have a 10 year term and an exercise price of $4.00. 25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal quarterly increments over the following 3 years. The fair value of the options on the grant date was $3.13 per share using the Black-Scholes Option pricing model. During February 2014, the Company granted to three directors, an aggregate of options to purchase 29,197 shares of common stock. Each option has a ten year term and an exercise price of $7.50 per share, respectively. 25% of the options vest on the one year anniversary of the grant date and the remaining options vest quarterly over the following 3 years. The fair value of the options at the grant date was approximately $4.55 per share using the Black-Scholes Option pricing model. During May 2014, the Company granted various employees options to purchase 70,000 shares of common stock, respectively. Each option has a 10 year term and an exercise price of $7.50 per share, respectively. 25% of the options vest on the one year anniversary of the grant date and the remaining options vest quarterly over the following 3 years. The fair value of the options on the grant date ranges were $3.58 per share using the Black-Scholes Option pricing model. During the year ended June 30, 2015, the Company granted to its current officers options to purchase 55,000 shares of common stock. Each option has a ten year term and an exercise price of $13.50 per share. 6.25% of the options vest each quarter over the following four years. The fair value of the options at the grant date was $9.08 per share using the Black-Scholes Option pricing model. During the year ended June 30, 2015, the Company granted various employees options to purchase 256,100 shares of common stock. Each option has a ten year term and has an exercise price ranging from $8.60 to $13.50 per share. A total of 135,400 options vest as follows: 25% on the one year anniversary of the grant date and the remaining options vest quarterly over the following 3 years. The remaining 120,700 options vest at a rate of 6.25% each quarter over 4 years. The fair value of the options on the grant date ranges from $3.59 to $9.96 per share using the Black-Scholes Option pricing model. A summary of the changes in options outstanding for the period from December 31, 2012 to June 30, 2015 is as follows: Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding and expected to vest at December 31, 2012 135,592 $ 4.00 9.5 $ - Granted 237,490 $ 4.00 Outstanding and expected to vest at December 31, 2013 373,082 $ 4.00 8.8 $ 1,305,000 Granted 299,952 $ 7.50 Outstanding and expected to vest at June 30, 2014 673,034 $ 5.56 9.2 $ 2,988,000 Granted 311,100 $ 12.63 Forfeited (206,504 ) $ 9.12 Outstanding and expected to vest at June 30, 2015 777,630 $ 7.44 8.6 $ 2,787,000 Options exercisable at June 30, 2015 301,499 $ 5.03 8.0 $ 1,557,000 At June 30, 2015, the Company has unrecognized stock-based compensation expense of approximately $2,496,400 related to unvested stock options over the weighted average remaining service period of 3.4 years. The weighted average fair value of options granted during the year ended June 30, 2015, for the six months ended June 30, 2014 and for the years ended December 31, 2013 was approximately $8.35, $3.60 and $2.90 per share respectively, on the date of grant using the Black-Scholes option pricing model with the following assumptions: Year Ended June 30, Six Months Year Ended December 31, Risk free interest rate 1.5% to 1.8 % 1.5 to 1.6 % 0.6 % Dividend yield 0 % 0 % 0 % Volatility 71% to 76 % 76% to 77 % 73% to 80 % Expected term (in years) 6.25 6.25 5.75 to 10 The following summarizes the components of stock-based compensation expense which includes stock options, warrants and restricted stock in the consolidated statements of operations for the year ended June 30, 2015, for the six months ended June 30, 2014, and for the year ended December 31, 2013, respectively: Year Ended June 30, Six Months Ended Year Ended December 31, 2014 Research and development $ 321,900 $ 115,500 $ 11,800 General and administrative 475,100 10,203,600 370,500 Total $ 797,000 $ 10,319,100 $ 382,300 During the year ended June 30, 2015, the Company granted 104,000 shares of restricted stock to employees which will be issued upon vesting. At June 30, 2015, there were 94,000 restricted stock awards outstanding of which, 10,000 were forfeited which had a fair value of $14.65 per share. The restricted stock grants vest over four years. The Company has an unrecognized expense of approximately $1,179,300, related to unvested restricted stock grants which will be recognized over the remaining weighted average service period of 3.7 years. The fair value per share of the restricted stock granted during the year ended June 30, 2015 was $13.80. Stock-based compensation - warrants During the year ended December 31, 2013, the Company issued 382,547 warrants in connection with Series A preferred stock offering, see Note 6 - Series A Preferred Stock. In connection with the subordinated promissory notes offerings during the year ended December 31, 2013, the Company issued the debt holders warrants to purchase 42,750 shares of common stock of the Company, exercisable at $4.00 per share. The Placement Agent was issued warrants to purchase 21,375 shares of common stock exercisable at $4.00 per share and expire in seven years. These warrants contained an anti-dilution features with down-round protection, thus the Company accounted for these warrants as derivative liabilities. The anti-dilution feature was eliminated upon the Share Exchange and the corresponding derivative liabilities were reclassified to additional paid-in capital. During 2012, the Company issued its founder 173,643 warrants to purchase common stock in connection with a transaction that exchanged debt for stock. These warrants were cancelled by the Company in January 2014 and in November 2014, the Company reissued the warrants back to the founder. The warrants have an exercise price of $4.00 per share and expire in five years. In December 2013, the Company purchased Medeor Inc. and in connection with the purchase, the Company issued the Placement Agent warrants to purchase 40,000 shares of common stock at an exercise price of $5.50 per share and expire in seven years. The Company recorded the fair value of stock-based compensation of $237,400 in connection with the issuance of these warrants based upon the Black-Scholes option pricing model. In conjunction with a strategic advisor agreement, to a related party, the Company issued warrants to purchase 1,731,157 shares of common stock (402,451 warrants for the year ended December 31, 2012, 321,285 warrants for the year ended December 31, 2013 and 1,007,421 warrants for the six months ended June 30, 2014) shares of common stock at a $0.001 exercise price and expire in May 2021. The warrants had a performance based requirement for vesting and became fully vested upon completion of a public transaction. During the six months ended June 30, 2014, the performance achievement was met. The Company recorded the fair value of stock-based compensation expense of approximately $10,119,000 based upon the Black-Scholes option pricing model. During the six months ended June 30, 2014, the Company issued 6,007,329 warrants in a connection with a common stock offering, see Note 6 - Common stock issued for cash. During the six months ended June 30, 2014 and for the year ended and December 31, 2013, the Company issued to consultants warrants to purchase 2,500 and 4,300 shares of common stock, respectively. The exercise price of the warrants issued during the six months ended June 30, 2014 and for the year ended December 31, 2013 were all at $4.00 per share. The grant date fair value of the warrants issued for the six months ended June 30, 2014 and for the year ended December, 31, 2013 was approximately $14,300 and $10,800, respectively, and the fair value was amortized over the term of the agreements. A summary of the changes in outstanding warrants during the year ended June 30, 2015, for the six months ended June 30, 2014 is as follows: Number of Shares Weighted Average Exercise Price Per Share Outstanding at December 31, 2012 973,046 $ 2.41 Granted 812,257 2.49 Outstanding at December 31, 2013 1,785,303 $ 2.41 Granted 7,017,251 $ 7.35 Forfeited (173,643 ) $ 4.00 Outstanding and vested at June 30, 2014 8,628,911 $ 6.40 Granted 173,643 $ 4.00 Exercised (2,040,277 ) $ 7.50 Forfeited (1,400,094 ) $ 7.50 Outstanding and vested at June 30, 2015 5,362,183 $ 5.60 At June 30, 2015, the Company has does not have any unrecognized stock based compensation expense related to outstanding warrants. At June 30, 2015, the aggregate intrinsic value of warrants vested and outstanding is approximately $26,270,000. There were no common stock warrants granted by the Company during the year ended June 30, 2015 other than the reissuance of the warrants to the founder. The weighted average fair value of warrants granted for the year ended June 30, 2015, for the six months ended June 30, 2014 and for the year ended December 31, 2013 was N/A, $7.00 per share and $4.00 per share, respectively, on the date of grant, using the Black-Scholes option pricing model using the following assumptions: Year Ended Six Months Year Ended Risk-free interest rate N/A 0.7% to 2.0 % 0.9% to 1.8 % Dividend yield N/A 0 % 0 % Expected volatility N/A 75% to 76 % 73% to 83 % Expected term (in years) N/A 4 and 7 4-7

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 7 - RELATED PARTY TRANSACTIONS Placement Agent On December 6, 2011, the Company entered into an engagement agreement with its placement agent (“Placement Agent”) for the Series A Preferred Stock and Notes Offering (collectively the “Financings”), of which Mr. Seth, a director of the Company, was also the former Head of Healthcare Investment Banking. The agreement was amended on April 12, 2012 and again on February 25, 2013. Pursuant to the agreement, the placement agent was engaged on an exclusive basis for the Series A Preferred Stock and Notes Offering and as a financial advisor for assisting the Company with the restructuring of its capitalization and negotiating the conversion of its outstanding debt obligations to enable a successful financing (the "Notes Conversion"). In consideration for its services, the placement agent received: (a) re-activation fee of $15,000, (b) a cash fee equal to 7% of the Notes Conversion and 10% of the gross proceeds raised in the Financings, and (c) non-accountable expense reimbursement equal to 2% of the gross proceeds raised. The placement agent or its designees also received warrants to purchase shares of the Company’s common stock in an amount equal to 10% of the shares of common stock and warrants issued or issuable as part of the units sold in the Series A Preferred Stock Offering and Notes Offerings. The agreement also contains certain provisions including termination as provider for in the agreement, see Note 5 on the warrants issued with respect to the Series A Preferred Stock and subordinated promissory notes. Due to the Share Exchange, the anti-dilution feature for the warrants that were issued for the Series A Preferred Stock and Notes Offering were terminated, see Note 5. There were Series A warrants, Series B warrants and Placement Agent warrants. See Note 5, Common Stock. These warrants contain an anti-dilution feature and shall terminate upon an up-listing to a national stock exchange, see Note 5. On October 24, 2013, the Company entered into an engagement agreement which was amended December 19, 2013 with its Placement Agent to advise on the acquisition of Medeor Inc. In consideration for its services, the Placement Agent was eligible to receive: (a) a cash success fee equal to 8% of the value of the transaction plus a 2% non-reimbursable expense fee which was subsequently modified to a maximum of $150,000 plus, (b) $50,000 for a Fairness Opinion fee deductible against the success fee, and (c) a $50,000 activation fee. The agreement also provided that: (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the Placement Agent, the placement agent would receive a fee equal to 8% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the Placement Agent will have the right to act as the Company’s financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the engagement agreement. On February 18, 2014 and May 19, 2014, the Company entered into two engagement agreements with the Placement Agent for the May 2014 offering The Company agreed to pay Placement Agent: (a) a cash commission in the amount of ten percent (10%) of the gross proceeds of the Offering received from investors at a Closing as well as a non-accountable expense reimbursement equal to two percent; and (b) (2%) of the gross proceeds of the Offering received from investors at a Closing and an activation fee of $25,000. The Placement Agent or its designees also received five-year warrants to purchase 858,190 shares of Relmada’s common stock at a price of $7.50 per share. The Placement Agent shall also be entitled to the compensation set forth above as well for any cash exercise of Warrants within six (6) months of the final closing of the Offering as well as a five percent (5%) solicitation fee for any Warrants exercised as a result of any redemption of any Warrants. If the Company elects to call the warrants, the Placement Agent shall receive a warrant solicitation fee equal to 5% of the funds solicited by the Placement Agent upon exercise of the warrants. The Company shall pay the Placement Agent a non-refundable financial advisory fee to be paid monthly, at the rate of $25,000 per month for a period of six months commencing after the May offerings. The Company extended the monthly $25,000 financial advisory fee to May 2015 and the Company did not renew the agreement. The Placement Agent also received cash proceeds from the Company of approximately $1,830,500, $3,089,500, $554,700, for the year ended June 30, 2015, for the six months ended June 30, 2014 and for the year ended December 31, 2013, respectively, from the warrant exercises from the warrant holders from the May and June 2014 equity offerings; and from the Series A preferred stock offerings. The Placement Agent received cash proceeds from the Company of $68,400 from the issuance of subordinated promissory notes issued during 2013. The Placement Agent received the following warrants during the year ended December 31, 2013: Number of warrants Exercise price per share Expiration Series A preferred offering 127,516 $ 4.00 2020 Subordinated promissory note offering 21,375 $ 4.00 2020 Acquisition of Medeor 40,000 $ 5.50 2020 188,891 The Placement Agent received the following warrants during the six months ended June 30, 2014: Number of warrants Exercise price per share Expiration May and June 2014 offering 858,190 $ 7.50 2019 Advisory Firm On December 6, 2011, the Company entered into an advisory agreement with Jamess Capital Group, LLC (formerly known as Amerasia Capital Group, LLC), a consulting firm affiliated with Mr. Seth, a Director of the Company (“Advisory Firm”) to provide non-investment banking related advisory services. The Advisory Firm is due a monthly fee of $12,500 and the agreement is terminable by either party with three months written notice and is to be issued fully vested warrants to purchase common stock equal to 12% of the outstanding capital stock of the Company as of the Share Exchange (exercisable at an exercise price of $0.001 per share), see Note 5. The Advisory Firm is also eligible to be reimbursed upon the submission of proper documentation for ordinary and necessary out-of-pocket expenses not to exceed $5,000 per month. This agreement was terminated effective June 30, 2015. On August 4, 2015, the Company entered into an Advisory and Consulting Agreement (the “Consulting Agreement”) with Sandesh Seth, the Company’s Chairman of the Board. The effective date of the Consulting Agreement is June 30, 2015. Mr. Seth has substantial experience in, among other matters, business development, corporate planning, corporate finance, strategic planning, investor relations and public relations, and an expansive network of connections spanning the biopharmaceutical industry, accounting, legal and corporate communications professions. Mr. Seth will provide advisory and consulting services to assist the Company with strategic advisory services, assist in prioritizing product development programs per strategic objectives, assist in recruiting of key personnel and directors, corporate planning, business development activities, corporate finance advice, and assist in investor and public relations services. In consideration for the services to be provided, the Company agrees to pay Mr. Seth $12,500 per month. Acquisition of Medeor In April 2012, the Company (sub licensee) entered into a license agreement with Medeor (licensee) and issued 683 shares of common stock for the license agreement. The Chief Executive Officer was a shareholder of Medeor. At December 31, 2013, the Company issued 100,000 shares of common stock in exchange for all the outstanding stock of Medeor whose only asset was a research and development project. The parties also amended the license agreement on December 31, 2013. The transaction was valued at its fair value of $3,750,000 and was expensed to research and development expense. The fair value of the shares was determined via a third party valuation. The Company will make royalty and a milestone payments as defined in the amended license agreement. The Company (A) will make royalty payments up to 2% on net sales of licensed products that are not sold by sub licensee and (B) on each and every sublicense earned royalty payment received by licensee from its sub licensee on sales of license product by sub-licensee, the higher of (i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sub-licensee. The Company will also make milestone payments of up to $4 million and up to $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2015
Income Taxes [Abstract]
INCOME TAXES	NOTE 8 - INCOME TAXES No provision or benefit for federal or state income taxes has been recorded because the Company has incurred net losses for all periods presented and has recorded a valuation allowance against its deferred tax assets. The components of the Company’s deferred tax assets are as follows at: June 30, June 30, Deferred tax assets: Net operating loss $ 8,257,000 $ 3,556,600 Stock-based compensation 4,268,200 4,248,700 Research and development tax credits 767,000 197,700 Accruals 46,400 22,900 Other 2,900 2,900 Valuation allowance (13,341,500 ) (8,028,800 ) Total $ - $ - The Company has maintained a full valuation allowance against its deferred tax at June 30, 2015 and 2014. A valuation allowance is required to be recorded when it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Since the Company cannot be assured of realizing the net deferred tax asset, a full valuation allowance has been provided. The valuation allowance increased for the years ended June 30, 2015 and for the six months ended June 30, 2014, by approximately $5,312,700 and $4,736,200, respectively. At June 30, 2015, the Company had federal net operating loss carryforwards of approximately $24,285,000, which begin expiring in 2027. The Company also had federal research and development tax credit carryforwards of approximately $767,000 which will begin to expire in 2027. The United States Tax Reform Act of 1986 contains provisions that may limit the Company’s net operating loss carryforwards available to be used in any given year in the event of significant changes in the ownership interests of significant stockholders, as defined. The effect of an ownership change would be the imposition of an annual limitation on the use of NOL carryforwards attributable to periods before the change. The amount of the annual limitation depends upon the value of the Company immediately before the change, changes to the Company’s capital during a specified period prior to the change, and the federal published interest rate. A reconciliation of the statutory tax rate to the effective tax rate is as follows: Year Ended June 30, Six Months Year Ended Statutory federal income tax rate 34 % 34 % 34 % State (net of federal benefit) 6.6 % 6.6 % 6.6 % Non-deductible expenses (9.7 )% (13.1 )% (29.7 )% Other 0.6 % (2.3 )% - Change in valuation allowance (31.5 )% (25.2 )% (10.9 )% Effective income tax rate 0 % 0 % 0 % The Company does not have any uncertain tax positions at June 30, 2015 and 2014 that would affect its effective tax rate. The Company does not anticipate a significant change in the amount of unrecognized tax benefits over the next twelve months. Because the Company is in a loss carryforward position, the Company is generally subject to US federal and state income tax examinations by tax authorities for all years for which a loss carryforward is available. If and when applicable, the Company will recognize interest and penalties as part of income tax expense.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2015
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 - COMMITMENTS AND CONTINGENCIES License Agreements Wonpung On August 20, 2007, the Company entered into a License Development and Commercialization Agreement with Wonpung, a shareholder of the Company. Wonpung has exclusive territorial rights in countries it selects in Asia to market up to two drugs the Company is currently developing and a right of first refusal (“ROFR”) for up to an additional five drugs that the Company may develop in the future as defined in more detail in the license agreement. The Company received an upfront license fee of $1,500,000 and will earn royalties of up to 12% of net sales for up to two licensed products it is currently developing. The licensing terms for the ROFR products are subject to future negotiations and binding arbitration. The terms of each licensing agreement will expire on the earlier of any time from 15 years to 20 years after licensing or on the date of commercial availability of a generic product to such licensed product in the licensed territory. The Company’s current focus is on developing and marketing its products in the United States and not Asia. It will be several years before the Company markets its products in Asia. Third Party Licensor Based upon the Medeor transaction, the Company assumed an obligation to pay a third party (A) royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product by sublicensee, the higher of (i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 million and up to $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively, see Note 7. Research and Development Contracts At June 30, 2015, the Company has approximately $3,985,000 in commitments, primarily related to its research and development contracts for its clinical research organizations through March 31, 2016. Leases The Company currently leases corporate office spaces for its New York City offices on a month-to month basis. The Company is planning on moving its New York City corporate office location in October 2015 to another space in New York City. The lease expires in December 2023. In addition, the Company has a lease expiring in 2017 for its Pennsylvania office location. Future minimum lease payments are as follows: For the year ended June 30: Year Amount 2016 $ 266,800 2017 357,800 2018 336,700 2019 335,100 2020 347,300 Thereafter 909,800 Total $ 2,553,500 The Company incurred rent expense of approximately $239,800, $13,300 and $ 67,800 and for year ended June 30, 2015, for the six months ended June 30, 2014, and for the year ended December 31, 2013, respectively. Letter Of Credit The Company has an outstanding letter of credit of approximately $390,800 in connection with the Company’s New York City corporate office lease. The letter of credit is secured by a restricted certificate of deposit in the same amount which is included in other assets at June 30, 2015. On the second anniversary of the commencement date which is expected to be in October 2017, the letter of credit will be reduced to approximately $234,400. In October 2022, the letter of credit will be reduced to approximately $156,000. Legal From time to time, the Company may become involved in lawsuits and other legal proceedings that arise in the course of business. Litigation is subject to inherent uncertainties, and it is not possible to predict the outcome of litigation with total confidence. Except as disclosed below, the Company is currently not aware of any legal proceedings or potential claims against it whose outcome would be likely, individually or in the aggregate, to have a material adverse effect on the Company’s business, financial condition or operating results. Lawsuit Brought by Former Officer Subsequently, Babul has brought a second lawsuit against Relmada, making claims for breach of contract, defamation, intentional infliction of emotional distress, and wrongful use of civil process. The Company has moved to dismiss Babul’s claims, brought in the United States District Court for the Eastern District of Pennsylvania. Management also believes that, if the litigation is permitted to proceed, it will have good defenses to all of Babul’s claims. However, litigation is an inherently uncertain process, and there can be no assurance that the Company will succeed in its defense. Management believes that the outcome of the Babul litigation, even if unfavorable, would not materially affect the Company’s operations or financial position.

Transition Period Comparable In

Transition Period Comparable Information (Unaudited)	12 Months Ended
	Jun. 30, 2015
Transition Period Comparable Information (Unaudited) [Abstract]
TRANSITION PERIOD COMPARABLE INFORMATION (UNAUDITED)	NOTE 10 - TRANSITION PERIOD COMPARABLE INFORMATION (UNAUDITED) The Company changed from a calendar year end to a fiscal year end for the period from January 1, 2014 to June 30, 2014. The Statements of Operations reflect a six month reporting period. For comparison purposes, we have disclosed twelve months of operations for the transition period and such information is used for the Management and Discussion Analysis. The following table presents certain unaudited financial information for the twelve months ended June 30, 2015 and 2014 and for the six months ended June 30, 2014 and 2013. For the Twelve Months Ended For the Six Months Ended 2015 2014 2014 2013 (Unaudited) (Unaudited) Statement of Operations Data: Operating expenses: Research and development $ (7,872,397 ) $ (5,380,077 ) $ (839,959 ) $ (708,551 ) General and administrative (9,226,883 ) (13,103,764 ) (12,106,859 ) (528,352 ) Total operating expenses (17,099,280 ) (18,483,841 ) (12,946,818 ) (1,236,903 ) Loss from operations Other (expenses) income: Loss on change in fair value of derivative liabilities (3,710,277 ) (8,971,343 ) (7,954,970 ) (11,861,302 ) Interest income 10,883 1,411 1,411 - Interest expense (4,922 ) (614,251 ) (435,611 ) (41,667 ) Total other expenses (3,704,316 ) (9,584,183 ) (8,389,170 ) (11,902,969 ) Net loss $ (20,803,596 ) $ (28,068,024 ) $ (21,335,988 ) $ (13,139,872 ) Net loss per common share - basic and diluted $ (2.09 ) $ (18.89 ) $ (8.65 ) $ (27.35 ) Weighted average common shares outstanding - basic and diluted 9,941,156 1,486,126 2,466,466 480,477 Statements of Cash Flows Data: Net cash used in operations $ (16,226,728 ) $ (7,213,709 ) $ (2,164,254 ) $ (992,190 ) Net cash used in investing activities (23,326 ) (11,740 ) (3,673 ) - Net cash provided by financing activities 13,155,663 31,230,072 24,209,828 779,096 Increase (decrease) in cash and cash equivalents $ (3,094,391 ) $ 24,004,623 $ 22,041,901 $ (213,094 )

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 - SUBSEQUENT EVENTS On August 4, 2015, the Company entered into a consulting agreement with a related party, see Note 7. Subsequent to June 30, 2015, the Company issued 36,439 shares of common stock from the exercise of warrants (28,939 warrants) and for the issuance of services (7,500 shares). In August 2015, the board approved an amendment to the Plan. Among other things, the Plan Amendment updates the definition of “change of control” and provides for accelerated vesting of all awards granted under the plan in the event of a change of control of the Company, see Note 6.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2015
Summary of Significant Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the Company’s accounts and those of the Company’s wholly owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are the valuation of derivative liabilities, stock-based compensation expenses and income taxes and its associated valuation allowance.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers cash deposits and all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company's cash deposits are held at two high-credit-quality financial institutions. The Company's cash deposits at these institutions exceed federally insured limits.
Patents	Patents Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.
Fixed Assets	Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Fixed assets are comprised of computers and software. Depreciation is calculated using the straight-line method over the estimated useful life of the related assets, which is three years.
Derivatives	Derivatives All derivatives are recorded at fair value on the balance sheet. The Company has determined fair values using market based pricing models incorporating readily prices and or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity) that requires judgment and estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments primarily include cash, derivative liabilities and accounts payable. Due to the short-term nature of cash, accounts payable and note payable, the carrying amounts of these assets and liabilities approximate their fair value. Derivatives are recorded at fair value at each period end. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows: Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means. Level 3 Inputs - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).
Fair Value on a Recurring Basis	Fair Value on a Recurring Basis As required by Accounting Standard Codification (“ASC”) Topic No. 820 - 10 Fair Value Measurement The following table sets forth, by level within the fair value hierarchy, the Company’s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2015: Quoted Prices In Active Significant Total Markets for Other Significant Carrying Identical Observable Unobservable Value as of Assets Inputs Inputs June 30, Description (Level 1) (Level 2) (Level 3) 2015 Derivative liabilities - warrant instruments $ - $ - $ 14,001,369 $ 14,001,369 The following table sets forth, by level within the fair value hierarchy, the Company’s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2014: Description Quoted Prices Significant Significant Unobservable Inputs Total Carrying Value as of June 30, Derivative liabilities - warrant instruments $ - $ - $ 25,586,933 $ 25,586,933 The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as level 3 in the fair value hierarchy: Significant Unobservable Inputs Year Six Months Year 2015 2014 2013 Beginning balance $ 25,586,933 $ 20,103,425 $ 5,090,988 Change in fair value of derivative liabilities included in net loss for the year ended June 30, 2015, for the six months ended June 30, 2014, and for the year ended December 31, 2013, respectively 3,710,277 7,954,970 12,877,675 Additions - warrant instruments - 4,333,163 373,699 Transfer of warrant instruments to additional paid-in-capital (15,295,841 ) (6,804,625 ) - Additions - conversion feature of Series A preferred stock - - 1,761,063 Ending balance $ 14,001,369 $ 25,586,933 $ 20,103,425
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is uncertain. At June 30, 2015 and 2014, the Company had recorded a valuation allowance to the full extent of the Company’s net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold. The Company files a U.S. Federal income tax return and various state returns. Uncertain tax positions taken on our tax returns will be accounted for as liabilities for unrecognized tax benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at June 30, 2015 and 2014. The open tax years, subject to potential examination by the applicable taxing authority, for the Company are from 2012 through 2014.
Research and Development	Research and Development Research and development costs primarily consist of research contracts for the advancement of product development, salaries and benefits, stock-based compensation, and consultants. The Company expenses all research and development costs in the period incurred. The Company makes an estimate of costs in relation to clinical study contracts. The Company analyzes the progress of studies, including the progress of clinical studies and phases, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability.
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics of those instruments. Compensation expense for warrants granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured, and is recognized over the service period. The expense is subsequently adjusted to fair value at the end of each reporting period until such warrants vest, and the fair value of such instruments, as adjusted, is expensed over the related vesting period. Adjustments to fair value at each reporting date may result in income or expense, depending upon the estimate of fair value and the amount of expense recorded prior to the adjustment. The Company reviews its agreements and the future performance obligation with respect to the unvested warrants for its vendors or consultants. When appropriate, the Company will expense the unvested warrants at the time when management deems the service obligation for future services has ceased.
Net Loss per Common Share	Net Loss per Common Share Basic net loss per common share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per common share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of Class A convertible preferred stock, Series A preferred stock, restricted stock awards, options and warrants to purchase common stock. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. Potentially dilutive securities are not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): Year Ended Six Months Year Ended December 31, Class A convertible preferred stock 71,672 667,462 - Series A preferred stock - - 2,720,826 Common stock warrants 5,362,183 8,628,911 1,785,303 Restricted stock awards 94,000 - - Common stock options 777,630 673,034 373,082 Total 6,305,485 9,969,407 4,879,211
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2014-12, Compensation—Stock Compensation. The amendments in this update apply to reporting entities that grant their employees stock-based payments in which the terms of the award provide that a performance target can be achieved after the requisite service period. The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, and early adoption is permitted. The Company is currently evaluating the effects of ASU 2014-12 on the consolidated financial statements. In August 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-15, Presentation of Financial Statements- Going Concern. The Update provides U.S. GAAP guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in this update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently evaluating the effects of ASU 2014-15 on the consolidated financial statements. The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of consolidated operations, consolidated financial position, or consolidated cash flows of the Company.
Subsequent Events	Subsequent Events The Company’s management reviewed all material events through the date the financial statements were issued for subsequent event disclosure consideration.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2015
Summary of Significant Accounting Policies [Abstract]
Fair value, financial liabilities measured on recurring basis	Quoted Prices In Active Significant Total Markets for Other Significant Carrying Identical Observable Unobservable Value as of Assets Inputs Inputs June 30, Description (Level 1) (Level 2) (Level 3) 2015 Derivative liabilities - warrant instruments $ - $ - $ 14,001,369 $ 14,001,369 The following table sets forth, by level within the fair value hierarchy, the Company’s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2014: Description Quoted Prices Significant Significant Unobservable Inputs Total Carrying Value as of June 30, Derivative liabilities - warrant instruments $ - $ - $ 25,586,933 $ 25,586,933
Fair value of the company level three financial liabilities	Quoted Prices In Active Significant Total Markets for Other Significant Carrying Identical Observable Unobservable Value as of Assets Inputs Inputs June 30, Description (Level 1) (Level 2) (Level 3) 2015 Derivative liabilities - warrant instruments $ - $ - $ 14,001,369 $ 14,001,369 The following table sets forth, by level within the fair value hierarchy, the Company’s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2014: Description Quoted Prices Significant Significant Unobservable Inputs Total Carrying Value as of June 30, Derivative liabilities - warrant instruments $ - $ - $ 25,586,933 $ 25,586,933 The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as level 3 in the fair value hierarchy: Significant Unobservable Inputs Year Six Months Year 2015 2014 2013 Beginning balance $ 25,586,933 $ 20,103,425 $ 5,090,988 Change in fair value of derivative liabilities included in net loss for the year ended June 30, 2015, for the six months ended June 30, 2014, and for the year ended December 31, 2013, respectively 3,710,277 7,954,970 12,877,675 Additions - warrant instruments - 4,333,163 373,699 Transfer of warrant instruments to additional paid-in-capital (15,295,841 ) (6,804,625 ) - Additions - conversion feature of Series A preferred stock - - 1,761,063 Ending balance $ 14,001,369 $ 25,586,933 $ 20,103,425
Summary of anti-dilutive securities	Year Ended Six Months Year Ended December 31, Class A convertible preferred stock 71,672 667,462 - Series A preferred stock - - 2,720,826 Common stock warrants 5,362,183 8,628,911 1,785,303 Restricted stock awards 94,000 - - Common stock options 777,630 673,034 373,082 Total 6,305,485 9,969,407 4,879,211

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	12 Months Ended
	Jun. 30, 2015
Prepaid Expenses [Abstract]
Schedule of prepaid expenses	June 30, June 30, Rent $ 450,700 $ 11,400 Research and development 565,100 - Insurance 337,100 77,600 Taxes 82,000 - Other 63,000 89,200 Total $ 1,497,900 $ 178,200

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	12 Months Ended
	Jun. 30, 2015
Derivative Liabilities [Abstract]
Summary of assumption used in valuation model of derivatives liabilities	June 30, June 30, 2015 2014 Common stock issuable upon exercise of warrants 2,574,570 6,007,330 Market value of common stock on measurement date (1) $ 10.15 $ 10.00 Exercise price $ 7.50 and 11.25 $ 7.50 and 11.25 Risk free interest rate (2) 1.6 % 1.6 % Expected life in years 3.9 0.3 and 4.9 Expected volatility (3) 70 % 71% and 73 % Expected dividend yields (4) None None (1) Quoted market value of the common stock, reflects a one-for-five reverse stock split. (2) The risk-free interest rate was determined by management using the applicable Treasury Bill interest rate as of the measurement date, when applicable. (3) The historical trading volatility was determined by calculating the volatility of the Company’s peer group. (4) The Company does not expect to pay a dividend in the foreseeable future.
Schedule of assumptions used in valuation model of derivatives warrants	Common stock issuable upon exercise of warrants 2,033,915 Market value of common stock on measurement date $ 15.00 Exercise price $ 7.50 Risk free interest rate 0.02 % Expected life in years 0.0 Expected volatility 71.2 % Expected dividend yields None
Schedule of fair value of derivative liabilities	Balance at Initial valuation of derivative Increase (decrease) in fair value of derivative Fair value of derivatives Balance at 2014 period liabilities capital 2015 Series A warrants issued in May and June 2014 offering $ 10,040,822 $ - $ 5,255,019 $ (15,295,841 ) $ - Series B warrants issued in connection with May and June 2014 offering 9,894,930 - (1,124,230 ) - 8,770,700 Placement Agent warrants issued in connection with May and June 2014 offering 5,651,181 - (420,512 ) - 5,230,669 Total $ 25,586,933 $ - $ (3,710,277 ) $ (15,295,841 ) $ 14,001,369 The following table sets forth, by level within the fair value hierarchy, the Company’s derivative liabilities that were accounted for at fair value on a recurring basis as June 30, 2014: Balance at December 31, Initial valuation of derivative Increase (decrease) in fair value of derivative Fair value of derivatives Balance at 2013 period liabilities capital 2014 Convertible preferred derivative liability issued in connection with Series A preferred stock offering $ 11,762,115 $ - $ (7,214,804 ) $ (4,547,311 ) $ - Convertible preferred derivative liability issued to Wonpung for services 2,030,589 - (1,370,262 ) (660,327 ) - Convertible preferred derivative liability issued to lenders in connection with exchange of debt for Series A preferred stock 2,219,854 - (1,262,858 ) (956,996 ) - Warrants issued in connection with Series A preferred stock offering 2,424,167 - (1,945,669 ) (478,498 ) - Warrants issued as offering costs to placement agent 1,217,083 - (1,109,421 ) (107,662 ) - Warrants issued to lenders in connection with subordinated promissory notes offering 313,258 - (259,427 ) (53,831 ) - Warrants issued to placement agent in connection with subordinated promissory notes offering 136,359 - (136,359 ) - - A warrants issued in May and June 2014 offering - 842,370 9,198,452 - 10,040,822 B warrants issued in connection with May and June 2014 offering - 2,494,655 7,400,275 - 9,894,930 Placement Agent warrants issued in connection with May and June 2014 offering - 996,138 4,655,043 - 5,651,181 Total $ 20,103,425 $ 4,333,163 $ 7,954,970 $ (6,804,625 ) $ 25,586,933 The following table sets forth, by level within the fair value hierarchy, the Company’s derivative liabilities that were accounted for at fair value on a recurring basis as of December 31, 2013: Balance at Initial valuation of derivative liabilities upon issuance of new warrants Increase in fair value of Balance at December 31, during derivative December 31, 2012 the period liabilities 2013 Convertible preferred derivative liability issued in connection with Series A preferred stock offering $ 2,492,166 $ 1,647,910 $ 7,622,039 $ 11,762,115 Convertible preferred derivative liability issued to Wonpung for services 880,214 - 1,150,375 2,030,589 Convertible preferred derivative liability issued to lenders in connection with exchange of debt for Series A preferred stock 958,861 - 1,260,993 2,219,854 Warrants issued in connection with Series A preferred stock offering 475,000 113,153 1,836,014 2,424,167 Warrants issued as offering costs to placement agent 242,500 248,655 725,928 1,217,083 Warrants issued to lenders in connection with subordinated promissory notes offering 29,158 83,363 200,737 313,258 Warrants issued to placement agent in connection with subordinated promissory notes offering 13,089 41,681 81,589 136,359 Total $ 5,090,988 $ 2,134,762 $ 12,877,675 $ 20,103,425

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Jun. 30, 2015
Class of Stock [Line Items]
Gross proceeds received in connection with offerings	Par value of common stock issued $ 3,433 Additional paid-in-capital 17,892,725 Derivative warrant liabilities 3,337,025 Derivative warrants issued to placement agent as offering costs 996,138 Net proceeds 22,229,321 Offering costs paid in cash 3,516,378 Gross proceeds $ 25,745,699
Summary of changes in options outstanding	Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding and expected to vest at December 31, 2012 135,592 $ 4.00 9.5 $ - Granted 237,490 $ 4.00 Outstanding and expected to vest at December 31, 2013 373,082 $ 4.00 8.8 $ 1,305,000 Granted 299,952 $ 7.50 Outstanding and expected to vest at June 30, 2014 673,034 $ 5.56 9.2 $ 2,988,000 Granted 311,100 $ 12.63 Forfeited (206,504 ) $ 9.12 Outstanding and expected to vest at June 30, 2015 777,630 $ 7.44 8.6 $ 2,787,000 Options exercisable at June 30, 2015 301,499 $ 5.03 8.0 $ 1,557,000
Weighted average fair value of options granted	Year Ended June 30, Six Months Year Ended December 31, Risk free interest rate 1.5% to 1.8 % 1.5 to 1.6 % 0.6 % Dividend yield 0 % 0 % 0 % Volatility 71% to 76 % 76% to 77 % 73% to 80 % Expected term (in years) 6.25 6.25 5.75 to 10
Schedule of share based compensation expense	Year Ended June 30, Six Months Ended Year Ended December 31, 2014 Research and development $ 321,900 $ 115,500 $ 11,800 General and administrative 475,100 10,203,600 370,500 Total $ 797,000 $ 10,319,100 $ 382,300
Summary of changes in warrants outstanding	Number of Shares Weighted Average Exercise Price Per Share Outstanding at December 31, 2012 973,046 $ 2.41 Granted 812,257 2.49 Outstanding at December 31, 2013 1,785,303 $ 2.41 Granted 7,017,251 $ 7.35 Forfeited (173,643 ) $ 4.00 Outstanding and vested at June 30, 2014 8,628,911 $ 6.40 Granted 173,643 $ 4.00 Exercised (2,040,277 ) $ 7.50 Forfeited (1,400,094 ) $ 7.50 Outstanding and vested at June 30, 2015 5,362,183 $ 5.60
Weighted average fair value of warrants granted	Year Ended Six Months Year Ended Risk-free interest rate N/A 0.7% to 2.0 % 0.9% to 1.8 % Dividend yield N/A 0 % 0 % Expected volatility N/A 75% to 76 % 73% to 83 % Expected term (in years) N/A 4 and 7 4-7
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Gross proceeds received in connection with offerings	Par value of Series A preferred stock issued $ 1,020 Additional paid-in-capital 1,483,690 Derivative warrant liabilities 113,153 Derivative preferred stock conversion feature 1,647,910 Derivative warrants issued to placement agent as offering costs 248,655 Offering costs paid in cash 586,072 Total $ 4,080,500

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Schedule of received warrants	The Placement Agent received the following warrants during the year ended December 31, 2013: Number of warrants Exercise price per share Expiration Series A preferred offering 127,516 $ 4.00 2020 Subordinated promissory note offering 21,375 $ 4.00 2020 Acquisition of Medeor 40,000 $ 5.50 2020 188,891 The Placement Agent received the following warrants during the six months ended June 30, 2014: Number of warrants Exercise price per share Expiration May and June 2014 offering 858,190 $ 7.50 2019

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2015
Income Taxes [Abstract]
Schedule of deferred tax assets	June 30, June 30, Deferred tax assets: Net operating loss $ 8,257,000 $ 3,556,600 Stock-based compensation 4,268,200 4,248,700 Research and development tax credits 767,000 197,700 Accruals 46,400 22,900 Other 2,900 2,900 Valuation allowance (13,341,500 ) (8,028,800 ) Total $ - $ -
Reconciliation of the statutory tax rate to the effective tax rate	Year Ended June 30, Six Months Year Ended Statutory federal income tax rate 34 % 34 % 34 % State (net of federal benefit) 6.6 % 6.6 % 6.6 % Non-deductible expenses (9.7 )% (13.1 )% (29.7 )% Other 0.6 % (2.3 )% - Change in valuation allowance (31.5 )% (25.2 )% (10.9 )% Effective income tax rate 0 % 0 % 0 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2015
Commitments and Contingencies [Abstract]
Schedule of future minimum lease payments	Year Amount 2016 $ 266,800 2017 357,800 2018 336,700 2019 335,100 2020 347,300 Thereafter 909,800 Total $ 2,553,500

Transition Period Comparable 26

Transition Period Comparable Information (Unaudited) (Tables)	12 Months Ended
	Jun. 30, 2015
Transition Period Comparable Information (Unaudited) [Abstract]
Schedule of financial Information	For the Twelve Months Ended For the Six Months Ended 2015 2014 2014 2013 (Unaudited) (Unaudited) Statement of Operations Data: Operating expenses: Research and development $ (7,872,397 ) $ (5,380,077 ) $ (839,959 ) $ (708,551 ) General and administrative (9,226,883 ) (13,103,764 ) (12,106,859 ) (528,352 ) Total operating expenses (17,099,280 ) (18,483,841 ) (12,946,818 ) (1,236,903 ) Loss from operations Other (expenses) income: Loss on change in fair value of derivative liabilities (3,710,277 ) (8,971,343 ) (7,954,970 ) (11,861,302 ) Interest income 10,883 1,411 1,411 - Interest expense (4,922 ) (614,251 ) (435,611 ) (41,667 ) Total other expenses (3,704,316 ) (9,584,183 ) (8,389,170 ) (11,902,969 ) Net loss $ (20,803,596 ) $ (28,068,024 ) $ (21,335,988 ) $ (13,139,872 ) Net loss per common share - basic and diluted $ (2.09 ) $ (18.89 ) $ (8.65 ) $ (27.35 ) Weighted average common shares outstanding - basic and diluted 9,941,156 1,486,126 2,466,466 480,477 Statements of Cash Flows Data: Net cash used in operations $ (16,226,728 ) $ (7,213,709 ) $ (2,164,254 ) $ (992,190 ) Net cash used in investing activities (23,326 ) (11,740 ) (3,673 ) - Net cash provided by financing activities 13,155,663 31,230,072 24,209,828 779,096 Increase (decrease) in cash and cash equivalents $ (3,094,391 ) $ 24,004,623 $ 22,041,901 $ (213,094 )

Business (Details)

Business (Details) - shares	Aug. 12, 2015	May. 31, 2014	Jun. 30, 2015	Jun. 30, 2014
Business Textuals [Abstract]
Share exchange agreement description		RTI shareholders exchanged 10 shares of RTI common stock for one share of our common stock.
Common stock, shares authorized			100,000,000	100,000,000
Preferred stock, shares authorized			200,000,000	200,000,000
Subsequent Event [Member]
Business Textuals [Abstract]
Reverse stock split ratio description	One-for-five reverse stock
Common Stock [Member]
Business Textuals [Abstract]
Common stock, shares authorized				500,000,000
Preferred Stock [Member]
Business Textuals [Abstract]
Preferred stock, shares authorized				200,000,000
Preferred Class A [Member]
Business Textuals [Abstract]
Preferred stock, shares authorized				3,500,000

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2013
Fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis
Derivative liabilities	$ 14,001,369	$ 25,586,933	$ 20,103,425
Carrying Value as of [Member]
Fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis
Derivative liabilities	$ 14,001,369	$ 25,586,933
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member]
Fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis
Derivative liabilities
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Derivative liabilities warrant instruments [Member]
Fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis
Derivative liabilities
Significant Other Observable Inputs (Level 2) [Member]
Fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis
Derivative liabilities
Significant Other Observable Inputs (Level 2) [Member] | Derivative liabilities warrant instruments [Member]
Fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis
Derivative liabilities
Significant Unobservable Inputs (Level 3) [Member]
Fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis
Derivative liabilities	$ 14,001,369	$ 25,586,933
Significant Unobservable Inputs (Level 3) [Member] | Derivative liabilities warrant instruments [Member]
Fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis
Derivative liabilities	$ 14,001,369	$ 25,586,933

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Details 1) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2015	Dec. 31, 2013
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Transfer of warrant instruments to additional paid-in-capital	$ (6,804,625)	$ (15,295,841)
Fair Value, Inputs, Level 3 [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Beginning balance	20,103,425	25,586,933	$ 5,090,988
Change in fair value of derivative liabilities included in net loss for the year ended June 30, 2015, the six months ended June 30, 2014 and for the year ended December 31, 2013, respectively	7,954,970	$ 3,710,277	12,877,675
Additions - warrant instruments	4,333,163		$ 373,699
Transfer of warrant instruments to additional paid-in-capital	$ (6,804,625)	$ (15,295,841)
Additions - conversion feature of Series A preferred stock			$ 1,761,063
Ending balance	$ 25,586,933	$ 14,001,369	$ 20,103,425

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Details 2) - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2015	Dec. 31, 2013
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Anti-dilutive securities	9,969,407	6,305,485	4,879,210
Class A convertible preferred stock [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Anti-dilutive securities	667,462	71,672
Series A Preferred Stock [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Anti-dilutive securities			2,720,825
Common stock warrants [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Anti-dilutive securities	8,628,911	5,362,183	1,785,303
Restricted stock awards [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Anti-dilutive securities		94,000
Common Stock Options [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Anti-dilutive securities	673,034	777,630	373,082

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Details Textual)	12 Months Ended
	Jun. 30, 2015
Significant Accounting Policies (Textual)
Useful life, assets	3 years

Prepaid Expenses (Details)

Prepaid Expenses (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Prepaid Expenses [Abstract]
Rent	$ 450,700	$ 11,400
Research and development	565,100
Insurance	337,100	$ 77,600
Taxes	82,000
Other	63,000	$ 89,200
Total	$ 1,497,911	$ 178,158

Notes Payable (Details)

Notes Payable (Details) - USD ($)	May. 06, 2014	Jul. 31, 2014	Jun. 30, 2014	Jun. 30, 2015	Dec. 31, 2013
Notes Payable (Textual)
Note payable issued in connection with director and officer insurance policy	$ 77,850		$ 77,850	$ 557,377
Interest rate		3.00%	3.40%	2.80%
Financing of insurance premiums by issuance of note payable		$ 293,200		$ 263,800
Notes payable			$ 58,400	$ 263,800

Derivative Liabilities (Details

Derivative Liabilities (Details) - Initial Valuation [Member] - $ / shares		6 Months Ended	12 Months Ended
		Jun. 30, 2014	Jun. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock issuable upon exercise of warrants		6,007,330	2,574,570
Market value of common stock on measurement date (1)	[1]	$ 10	$ 10.15
Risk free interest rate (2)	[2]	1.60%	1.60%
Expected life in years			3 years 10 months 24 days
Expected volatility (3)	[3]		70.00%
Expected dividend yields (4)	[4]
Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Exercise price		$ 11.25	$ 11.25
Expected life in years		4 years 10 months 24 days
Expected volatility (3)	[3]	73.00%
Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Exercise price		$ 7.50	$ 7.50
Expected life in years		3 months 18 days
Expected volatility (3)	[3]	71.00%
[1]	Quoted market value of the common stock, reflects a one for five reverse stock split.
[2]	The risk-free interest rate was determined by management using the applicable Treasury Bill interest rate as of the measurement date, when applicable.
[3]	The historical trading volatility was determined by calculating the volatility of the Company's peer group.
[4]	The Company does not expect to pay a dividend in the foreseeable future.

Derivative Liabilities (Detai35

Derivative Liabilities (Details 1) - Jun. 30, 2015 - Warrant [Member] - $ / shares	Total
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock issuable upon exercise of warrants	2,033,915
Market value of common stock on measurement date	$ 15
Exercise price	$ 7.50
Risk free interest rate	0.02%
Expected life in years
Expected volatility	71.20%
Expected dividend yields

Derivative Liabilities (Detai36

Derivative Liabilities (Details 2) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2015	Dec. 31, 2013
Derivative [Line Items]
Balance Beginning	$ 20,103,425	$ 25,586,933	$ 5,090,988
Initial valuation of derivative liabilities upon issuance of new warrants during the period	4,333,163		2,134,762
Increase (decrease) in fair value of derivative liabilities	7,954,970	$ 3,710,277	12,877,675
Fair value of derivatives upon reclass to additional paid-in-capital	(6,804,625)	(15,295,841)
Balance Ending	$ 25,586,933	14,001,369	$ 20,103,425
Placement Agent [Member]
Derivative [Line Items]
Balance Beginning		$ 5,651,181
Initial valuation of derivative liabilities upon issuance of new warrants during the period	$ 996,138
Increase (decrease) in fair value of derivative liabilities	$ 4,655,043	$ (420,512)
Fair value of derivatives upon reclass to additional paid-in-capital
Balance Ending	$ 5,651,181	$ 5,230,669
Convertible preferred derivative liability issued in connection with Series A preferred stock offering [Member]
Derivative [Line Items]
Balance Beginning	$ 11,762,115		$ 2,492,166
Initial valuation of derivative liabilities upon issuance of new warrants during the period			1,647,910
Increase (decrease) in fair value of derivative liabilities	$ (7,214,804)		7,622,039
Fair value of derivatives upon reclass to additional paid-in-capital	$ (4,547,311)
Balance Ending			11,762,115
Convertible preferred derivative liability issued to Wonpung for services [Member]
Derivative [Line Items]
Balance Beginning	$ 2,030,589		880,214
Initial valuation of derivative liabilities upon issuance of new warrants during the period
Increase (decrease) in fair value of derivative liabilities	$ (1,370,262)		1,150,375
Fair value of derivatives upon reclass to additional paid-in-capital	$ (660,327)
Balance Ending			2,030,589
Convertible preferred derivative liability issued to lenders in connection with exchange of debt for Series A preferred stock [Member]
Derivative [Line Items]
Balance Beginning	$ 2,219,854		958,861
Initial valuation of derivative liabilities upon issuance of new warrants during the period
Increase (decrease) in fair value of derivative liabilities	$ (1,262,858)		1,260,993
Fair value of derivatives upon reclass to additional paid-in-capital	$ (956,996)
Balance Ending			2,219,854
Warrants issued in connection with Series A preferred stock offering [Member]
Derivative [Line Items]
Balance Beginning	$ 2,424,167		47,500
Initial valuation of derivative liabilities upon issuance of new warrants during the period			113,153
Increase (decrease) in fair value of derivative liabilities	$ (1,945,669)		1,836,014
Fair value of derivatives upon reclass to additional paid-in-capital	$ (478,498)
Balance Ending			2,424,167
Warrants issued as offering costs to placement agent [Member]
Derivative [Line Items]
Balance Beginning	$ 1,217,083		242,500
Initial valuation of derivative liabilities upon issuance of new warrants during the period			248,655
Increase (decrease) in fair value of derivative liabilities	$ (1,109,421)		725,928
Fair value of derivatives upon reclass to additional paid-in-capital	$ (107,662)
Balance Ending			1,217,083
Warrants issued to lenders in connection with subordinated promissory notes offering [Member]
Derivative [Line Items]
Balance Beginning	$ 313,258		29,158
Initial valuation of derivative liabilities upon issuance of new warrants during the period			83,363
Increase (decrease) in fair value of derivative liabilities	$ (259,427)		200,737
Fair value of derivatives upon reclass to additional paid-in-capital	$ (53,831)
Balance Ending			313,258
Warrants issued to placement agent in connection with subordinated promissory notes offering [Member]
Derivative [Line Items]
Balance Beginning	$ 136,359		13,089
Initial valuation of derivative liabilities upon issuance of new warrants during the period			41,681
Increase (decrease) in fair value of derivative liabilities	$ (136,359)		81,589
Fair value of derivatives upon reclass to additional paid-in-capital
Balance Ending			$ 136,359
A warrants [Member]
Derivative [Line Items]
Balance Beginning		$ 10,040,822
Initial valuation of derivative liabilities upon issuance of new warrants during the period	$ 842,370
Increase (decrease) in fair value of derivative liabilities	$ 9,198,452	$ 5,255,019
Fair value of derivatives upon reclass to additional paid-in-capital		$ (15,295,841)
Balance Ending	$ 10,040,822
B warrants [Member]
Derivative [Line Items]
Balance Beginning		$ 9,894,930
Initial valuation of derivative liabilities upon issuance of new warrants during the period	$ 2,494,655
Increase (decrease) in fair value of derivative liabilities	$ 7,400,275	$ (1,124,230)
Fair value of derivatives upon reclass to additional paid-in-capital
Balance Ending	$ 9,894,930	$ 8,770,700

Derivative Liabilities (Detai37

Derivative Liabilities (Details Textual) - 12 months ended Jun. 30, 2015 - shares	Total
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Risk free interest rate duration measurement	1 to 5 year Treasury Bill as of the measurement date.
Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Number of Shares, exercisable	2,033,915
Number of warrants, expired	1,398,845

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Par value of common stock issued		$ 1,020
Additional paid-in-capital		1,483,690
Derivative warrant liabilities		113,153
Derivative preferred stock conversion feature		1,647,910
Derivative warrants issued to placement agent as offering costs		248,655
Offering costs paid in cash		586,072
Gross proceeds		$ 4,080,500
Common Stock
Class of Stock [Line Items]
Par value of common stock issued	$ 3,433
Additional paid-in-capital	17,892,725
Derivative warrant liabilities	3,337,025
Derivative warrants issued to placement agent as offering costs	996,138
Net proceeds	22,229,321
Offering costs paid in cash	3,516,378
Gross proceeds	$ 25,745,699

Stockholders' Equity (Details 1

Stockholders' Equity (Details 1) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2015	Dec. 31, 2013	Dec. 31, 2012
Stockholders' Equity [Abstract]
Number of Shares, Outstanding	373,082	673,034	135,592
Number of Shares, Granted	299,952	311,100	237,490
Number of Shares, Forfeited		(206,504)
Number of Shares, Outstanding and expected to vest	673,034	777,630	373,082	135,592
Number of Shares, exercisable		301,499
Weighted Average Exercise Price Per Share, Outstanding	$ 4	$ 5.55	$ 4
Weighted Average Exercise Price Per Share, Granted	7.50	12.63	4
Weighted Average Exercise Price Per Share, Forfeited		9.12
Weighted Average Exercise Price Per Share, Outstanding and expected to vest	$ 5.55	7.44	$ 4	$ 4
Weighted Average Exercise Price Per Share, exercisable		$ 5.03
Weighted Average Remaining Contractual Term, Outstanding	9 years 2 months 12 days	8 years 7 months 6 days	8 years 9 months 18 days	9 years 6 months
Weighted Average Remaining Contractual Term, exercisable		8 years
Aggregate Intrinsic Value, Outstanding	$ 1,305,000	$ 3,000,000
Aggregate Intrinsic Value, Outstanding	$ 3,000,000	2,787,000	$ 1,305,000
Aggregate Intrinsic Value, exercisable		$ 1,557,000

Stockholders' Equity (Details 2

Stockholders' Equity (Details 2) - Stock Option [Member]	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2015	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate			0.60%
Risk-free interest rate, minimum	1.50%
Risk-free interest rate, maximum	1.60%
Dividend yield	0.00%	0.00%	0.00%
Volatility, minimum	76.00%		73.00%
Volatility, maximum	77.00%		80.00%
Expected term (in years)	6 years 3 months	6 years 3 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate		1.80%
Volatility		76.00%
Expected term (in years)			10 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate		1.50%
Volatility		71.00%
Expected term (in years)			5 years 9 months

Stockholders' Equity (Details 3

Stockholders' Equity (Details 3) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2015	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 10,319,100	$ 797,000	$ 382,300
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	115,500	321,900	11,800
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 10,203,600	$ 475,100	$ 370,500

Stockholders' Equity (Details 4

Stockholders' Equity (Details 4) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2015	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	8,926,517		4,865,234
Number of Shares, Outstanding and vested			8,926,517
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	1,785,303	8,628,911	973,046
Number of Shares, Granted	7,017,251	173,643	812,257
Number of Shares, Exercised		(2,040,278)
Number of Shares, Forfeited	(173,643)	(1,400,094)
Number of Shares, Outstanding and vested	8,628,911	5,362,183	1,785,303
Weighted Average Exercise Price Per Share, Outstanding	$ 2.70	$ 6.40	$ 2.41
Weighted Average Exercise Price Per Share, Granted	7.35	4	2.49
Weighted Average Exercise Price Per Share, Exercised		7.50
Weighted Average Exercise Price Per Share, Forfeited	4	7.50
Weighted Average Exercise Price Per Share, Outstanding and vested	$ 6.40	$ 5.60	$ 2.70

Stockholders' Equity (Details 5

Stockholders' Equity (Details 5) - Warrants [Member]	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2015	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate, minimum	0.70%		0.90%
Risk-free interest rate, maximum	2.00%		1.80%
Risk free interest rate
Dividend yield	0.00%		0.00%
Volatility, minimum	75.00%		73.00%
Volatility, maximum	76.00%		83.00%
Volatility
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	7 years		7 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	4 years		4 years

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - Equity Award [Domain] - USD ($)	May. 20, 2014	May. 31, 2014	Jun. 30, 2014	Jun. 30, 2015	Dec. 31, 2013	Nov. 30, 2014	Dec. 31, 2012
Class of Stock [Line Items]
Common stock conversion basis	One for one
Common stock conversion beneficially, Description	More than 9.9
Lenders amount				$ 390,800
Warrants issued, number of shares of common stock			6,007,329
Exercise price per share			$ 4		$ 0.001	$ 4
Proceeds from sale of Series A preferred stock
Placement agent expenses				$ 3,516,000
Ownership percentage of Relmada	94.60%
Issuance of shares in exchange for ownership interest	5,658,215
Percentage of acquired shares	80.90%
Stock split ratio description				The outstanding options and warrants were exchanged for options and warrants to purchase shares of common stock of the Company at a ratio of 10 to 1.
Issuance of common stock and Class A preferred stock in connection with share exchange			$ 2,000,000
Proceeds from sale of Series A preferred stock and warrants					$ 3,494,428
Class A convertible preferred stock
Class of Stock [Line Items]
Issuance of common stock for services, Shares
Issuance of common stock and Class A preferred stock in connection with share exchange			$ 667
Issuance of common stock and Class A preferred stock in connection with share exchange, Shares			667,462
Conversion of shares	667,462			(595,790)
Issuance of Series A preferred stock and warrants for cash, net of offering costs, Shares
Common Stock
Class of Stock [Line Items]
Issuance of common stock for services, Shares			5,810	83,333	11,279
Gross proceeds from issuance of offering costs			$ 25,745,699
Issuance of common stock and Class A preferred stock in connection with share exchange			$ 667
Issuance of common stock and Class A preferred stock in connection with share exchange, Shares			667,462
Conversion of shares				595,790
Issuance of Series A preferred stock and warrants for cash, net of offering costs, Shares
Series A Preferred Stock Offerings [Member]
Class of Stock [Line Items]
Warrants issued, number of shares of common stock					382,547
Placement Agent [Member]
Class of Stock [Line Items]
Exercise price per share							$ 4
Gross proceeds from issuance of offering costs				$ 22,229,300
Placement Agent [Member] | Series A Preferred Stock Offerings [Member]
Class of Stock [Line Items]
Warrants issued, number of shares of common stock					127,516
Exercise price per share					$ 4
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares converted to common stock		2,720,826
Exercise price per share			$ 0.80	$ 0.80	$ 4		$ 0.08
Warrant to purchase of common stock					255,031
Gross proceeds from issuance of offering costs					$ 4,080,500
Conversion of shares				595,790
Issuance of Series A preferred stock and warrants for cash, net of offering costs, Shares					1,020,125
Series A warrants [Member]
Class of Stock [Line Items]
Warrants issued, number of shares of common stock				3,432,760
Exercise price per share				$ 7.50
Series B warrants [Member]
Class of Stock [Line Items]
Warrants issued, number of shares of common stock				1,716,379
Exercise price per share			$ 2.25	$ 11.25
Warrants redemption terms				The Company may call the B warrants for redemption upon written notice to all investors of the May and June 2014 units (“investors”) at any time if the closing price of the common stock exceeds $18.75 per share for twenty consecutive trading days provided that there is an effective registration statement. Sixty business days following the date the redemption notice (“Exercise Period”) is sent to the investors, each may choose to exercise their B warrants or a portion of their B warrants, by paying the exercise price of $11.25 per share. Any warrants not exercised on the last day of the Exercise Period, will be redeemed by the Company at $0.001 per share.
Percentage of solicitation fee on warrants exercised				5.00%
Agent warrants [Member]
Class of Stock [Line Items]
Warrants issued, number of shares of common stock				858,190
Exercise price per share				$ 7.50

Stockholders' Equity (Details45

Stockholders' Equity (Details Textual 1)	May. 20, 2014USD ($)	Jan. 10, 2014shares	Jul. 10, 2013shares	Jul. 10, 2012shares	Nov. 30, 2014$ / shares	Jun. 10, 2014USD ($)	Jun. 30, 2014USD ($)$ / sharesshares	Jun. 30, 2015USD ($)Installments$ / sharesshares	Dec. 31, 2013USD ($)$ / sharesshares	Dec. 31, 2012USD ($)$ / sharesshares	Apr. 30, 2012$ / shares
Class of Stock [Line Items]
Aggregate proceeds from private placement | $						$ 25,745,700	$ 22,229,300
Warrant to purchase of common stock, Value | $								$ 6,300
Term of warrants					5 years
Exercise price per share | $ / shares					$ 4		$ 4		$ 0.001
Issuance of common stock for services | $							$ 8,714	1,180,410	$ 16,918
Stock-based compensation expense | $							$ 10,319,100	$ 797,000	$ 382,300
Number of Shares, Granted							299,952	311,100	237,490
Share based compensation shares vested								135,400
Issuance of common stock to founder for cash | $	$ 2,000,000
Common stock, par value | $ / shares							$ 0.001	$ 0.001
Research and development | $							$ 839,959	$ 7,872,397	$ 5,248,669
Common stock, shares outstanding							8,058,843	10,778,474
Consultants [Member]
Class of Stock [Line Items]
Warrant to purchase of common stock							2,500		4,300
Warrant to purchase of common stock, Value | $								$ 25,500
Exercise price per share | $ / shares							$ 4		$ 4	$ 4
Issuance of common stock for services, Shares								483,333
Issuance of common stock for services | $								$ 1,180,400
Shares issued for other services								16,667
Number of installments | Installments								2
Common Stock [Member]
Class of Stock [Line Items]
Issuance of common stock for services, Shares							5,810	83,333	11,279
Issuance of common stock for services | $							$ 6	$ 84	$ 11
Number of Shares, Granted										1,538,010
Fair value of the common granted | $										$ 46,100
Grant date fair value of the common stock | $ / shares										$ 0.03
Common Stock [Member] | Medeor Inc [Member]
Class of Stock [Line Items]
Exercise price per share | $ / shares											$ 0.30
Common stock issued for services [Member]
Class of Stock [Line Items]
Stock-based compensation expense | $							$ 8,700		$ 16,900
Common stock per share | $ / shares										$ 1.50
Number of Shares, Granted										30,760
Fair value of the common granted | $										$ 46,100
Share based compensation shares vested		5,812	11,278	13,670
Series A warrants [Member]
Class of Stock [Line Items]
Warrant to purchase of common stock								2,033,915
Exercise price per share | $ / shares								$ 7.50
Series A warrants [Member] | Consultants [Member]
Class of Stock [Line Items]
Issuance of common stock and warrants to purchase common stock								6,512

Stockholders' Equity (Details46

Stockholders' Equity (Details Textual 2) - USD ($)

1 Months Ended

6 Months Ended

12 Months Ended

May. 31, 2014

Feb. 28, 2014

Jan. 31, 2014

Nov. 30, 2013

Sep. 30, 2013

Jun. 30, 2014

Jun. 30, 2015

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Nov. 30, 2014

Jul. 31, 2012

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Number of shares available for future grants under stock option plan

740,138

Stock options plan stock options exercisable period

10 years

Stock options exercisable period description

Vest over four years

Stock-based compensation expense

$ 10,119,000

Share based compensation shares vested

135,400

Unrecognized stock based compensation expense

$ 1,760,900

$ 2,496,400

$ 589,500

$ 0

Weighted average fair value of options and warrants granted

$ 3.60

$ 8.35

$ 2.90

Unrecognized stock based compensation, weighted average remaining period

3 years 4 months 24 days

Warrants issued, number of shares of common stock

6,007,329

Exercise price per share

$ 4

$ 0.001

$ 4

Unvested warrants to purchase common stock

1,731,157

Fair value of warrants issued

$ 14,300

$ 10,800

Number of shares increased by shareholders

1,611,769

Shares of restricted stock granted to employees

104,000

Shares of restricted stock granted to employees, Net

94,000

Restricted shares, Forfeited

10,000

Fair value per share of the restricted stock

$ 2.68

Forfeited shares of common stock

(206,504)

Board of Directors [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Options to purchase of common stock

29,197

Stock options term

10 years

Options vest percentgae

25.00%

Remaining options vest period description

Options vest on the one year anniversary of the grant date and the remaining options vest quarterly over the following 3 years.

Fair value of options

$ 4.55

Exercise price per share

$ 7.50

Placement Agent [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Exercise price per share

$ 4

Placement Agent [Member] | Medeor Inc [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock-based compensation expense

$ 237,400

Exercise price per share

$ 5.50

Warrant to purchase of common stock

40,000

Consultants [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Exercise price per share

$ 4

$ 4

$ 4

Warrant to purchase of common stock

2,500

4,300

Fair value of warrants issued

$ 0

Series A Preferred Stock Offerings [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock options term

7 years

7 years

Warrants issued, number of shares of common stock

382,547

Warrants contractual term

7 years

Series A Preferred Stock Offerings [Member] | Placement Agent [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Warrants issued, number of shares of common stock

127,516

Exercise price per share

$ 4

Debt Offerings [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock options term

7 years

7 years

Warrants contractual term

7 years

Debt Offerings [Member] | Debt Holders [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Warrants issued, number of shares of common stock

42,750

Exercise price per share

$ 4

Debt Offerings [Member] | Placement Agent [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Warrants issued, number of shares of common stock

21,375

Exercise price per share

$ 4

Strategic Advisor Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Exercise price per share

$ 0.01

Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Weighted average fair value of options and warrants granted

$ 0.72

0.58

$ 0.15

Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Weighted average fair value of options and warrants granted

$ 7

$ 4

Unvested warrants to purchase common stock

1,007,421

321,285

402,451

Aggregate intrinsic value of warrants vested

$ 26,270,000

Aggregate intrinsic value of warrants outstanding

$ 26,270,000

Founder Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Warrant to purchase of common stock

173,643

Officer Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Options to purchase of common stock

200,755

37,500

133,150

55,000

66,840

Stock options term

10 years

10 years

10 years

10 years

10 years

Options vest percentgae

25.00%

25.00%

25.00%

6.25%

25.00%

Remaining options vest percentage

75.00%

Remaining options vest period description

Options vest on the one anniversary of the grant date and the remaining options vest quarterly over the following 3 years

Options vest on the one year anniversary of the grant date and the remaining options vest in equal quarterly increments over the following 3 years.

Options vest in equal quarterly increments over a four-year period.

Options vest each quarter over the following 4 years.

Options vest on the one anniversary of the grant date and the remaining options vest quarterly over the following 3 years

Fair value of options

$ 4.55

$ 3.13

$ 2.70

$ 9.08

$ 2.71

Fair value of options on grant date

$ 454,000

Exercise price per share

$ 7.50

$ 4

$ 4

$ 13.50

$ 4

$ 0.80

Forfeited shares of common stock

150,566

Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Unrecognized stock based compensation expense

$ 1,179,300

Unrecognized stock based compensation, weighted average remaining period

3 years 8 months 12 days

Fair value per share of the restricted stock

$ 2.76

Employees Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock options plan stock options exercisable period

10 years

Options to purchase of common stock

70,000

256,100

Stock options term

10 years

Options vest percentgae

25.00%

Remaining options vest percentage

6.25%

Remaining options vest period description

Options vest on the one year anniversary of the grant date and the remaining options vest quarterly over the following 3 years.

Exercise price per share

$ 7.50

Employees Options [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Fair value of options on grant date

$ 3,580

$ 3,590

Exercise price per share

$ 8.60

Employees Options [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Fair value of options on grant date

$ 9,960

Exercise price per share

$ 13.50

Related Party Transactions (Det

Related Party Transactions (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Nov. 30, 2014
Class of Warrant or Right [Line Items]
Exercise price per share	$ 4	$ 0.001	$ 4
Placement Agent [Member]
Class of Warrant or Right [Line Items]
Number of warrants	858,190	188,891
Exercise price per share	$ 7.50
Expiration	2,019
Placement Agent [Member] | Series A Preferred stock
Class of Warrant or Right [Line Items]
Number of warrants		127,516
Exercise price per share		$ 4
Expiration		2,020
Placement Agent [Member] | Subordinated promissory note offering [Member]
Class of Warrant or Right [Line Items]
Number of warrants		21,375
Exercise price per share		$ 4
Expiration		2,020
Placement Agent [Member] | Acquisition of Medeor [Member]
Class of Warrant or Right [Line Items]
Number of warrants		40,000
Exercise price per share		$ 5.50
Expiration		2,020

Related Party Transactions (D48

Related Party Transactions (Details Textual)	May. 20, 2014USD ($)	Dec. 06, 2011USD ($)$ / shares	May. 31, 2015USD ($)	Nov. 30, 2014	May. 19, 2014USD ($)Installments	Oct. 24, 2013	Apr. 30, 2012shares	Jun. 30, 2014USD ($)shares	Jun. 30, 2015USD ($)$ / sharesshares	Dec. 31, 2013USD ($)shares
Class of Warrant or Right [Line Items]
Term of warrants				5 years
Proceeds from sale of Series A preferred stock
Issuance of common stock to founder for cash	$ 2,000,000
Issuance of common stock to acquire Medeor, Inc. at fair value, Shares | shares							683
Research and development expense										$ 3,750,000
Common Stock
Class of Warrant or Right [Line Items]
Issuance of common stock for services, Shares | shares								5,810	83,333	11,279
Issuance of common stock to acquire Medeor, Inc. at fair value, Shares | shares										100,000
Medeor [Member]
Class of Warrant or Right [Line Items]
Royalty payments description									(A) royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product.
Royalty received by licensee description									(i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 million and up to $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively.
Placement Agent [Member]
Class of Warrant or Right [Line Items]
Advisory services fees			$ 25,000						$ 25,000
Percent of fully vested warrants to purchase common stock									5.00%
Exercise price per share | $ / shares									$ 7.50
Issuance of warrants to purchase common stock | shares									858,190
Issuance of warrants to purchase common stock description									The Placement Agent shall also be entitled to the compensation set forth above as well for any cash exercise of Warrants within six (6) months of the final closing of the Offering as well as a five percent (5%) solicitation fee for any Warrants exercised as a result of any redemption of any Warrants. If the Company elects to call the warrants, the Placement Agent shall receive a warrant solicitation fee equal to 5% of the funds solicited by the Placement Agent upon exercise of the warrants.
Term of warrants									5 years
Proceeds from sale of Series A preferred stock								$ 3,089,500	$ 1,830,500	$ 554,700
Proceeds from issuance of subordinated promissory notes										$ 68,400
Related party transaction, Description of Transaction		In consideration for its services, the placement agent received: (a) re-activation fee of $15,000, (b) a cash fee equal to 7% of the Notes Conversion and 10% of the gross proceeds raised in the Financings, and (c) non-accountable expense reimbursement equal to 2% of the gross proceeds raised. The placement agent or its designees also received warrants to purchase shares of the Company's common stock in an amount equal to 10% of the shares of common stock and warrants issued or issuable as part of the units sold in the Series A Preferred Stock Offering and Notes Offerings.				In consideration for its services, the Placement Agent was eligible to receive: (a) a cash success fee equal to 8% of the value of the transaction plus a 2% non-reimbursable expense fee which was subsequently modified to a maximum of $150,000 plus, (b) $50,000 for a Fairness Opinion fee deductible against the success fee, and (c) a $50,000 activation fee.
Offering price description					(a) a cash commission in the amount of ten percent (10%) of the gross proceeds of the Offering received from investors at a Closing as well as a non-accountable expense reimbursement equal to two percent; and (b) (2%) of the gross proceeds of the Offering received from investors at a Closing and an activation fee of $25,000.
Number of agreements | Installments					2
Activation fee					$ 25,000
Business acquisition, Description						8% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the services.
Advisory Firm [Member]
Class of Warrant or Right [Line Items]
Advisory services fees		$ 12,500							12,500
Percent of fully vested warrants to purchase common stock		12.00%
Exercise price per share | $ / shares		$ 0.001
Maximum reimbursement expenses, monthly									$ 5,000

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Deferred tax assets:
Net operating loss	$ 8,257,000	$ 3,556,600
Stock based compensation	4,268,200	4,248,700
Research and development tax credits	767,000	197,700
Accruals	46,400	22,900
Other	2,900	2,900
Valuation allowance	$ (13,341,500)	$ (8,028,800)
Total

Income Taxes (Details 1)

Income Taxes (Details 1)	6 Months Ended	12 Months Ended
	Dec. 31, 2014	Jun. 30, 2015	Dec. 31, 2013
Reconciliation of the statutory tax rate to the effective tax rate
Statutory federal income tax rate	34.00%	34.00%	34.00%
State (net of federal benefit)	6.60%	6.60%	6.60%
Non-deductible expenses	(13.10%)	(9.70%)	(29.70%)
Other	(2.30%)	0.60%
Change in valuation allowance	(25.20%)	(31.50%)	(10.90%)
Effective income tax rate	0.00%	0.00%	0.00%

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Tax Credit Carryforward [Line Items]
Federal and state net operating loss carryforwards		$ 24,285,000
Tax credit carryforwards, expiring date	Dec. 31, 2027
Net operating loss carryforwards, limit description	The United States Tax Reform Act of 1986 contains provisions that may limit the Company's net operating loss carryforwards available to be used in any given year in the event of significant changes in the ownership interests of significant stockholders, as defined. The effect of an ownership change would be the imposition of an annual limitation on the use of NOL carryforwards attributable to periods before the change. The amount of the annual limitation depends upon the value of the Company immediately before the change, changes to the Company's capital during a specified period prior to the change, and the federal published interest rate.
Valuation allowance for deferred tax assets	$ 5,312,700	4,736,200
Federal research and development tax credit carryforwards [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards		$ 767,000
Federal and state net operating loss carryforwards, expiring date	Dec. 31, 2027

Commitments and Contingencies52

Commitments and Contingencies (Details)	Jun. 30, 2015USD ($)
Schedule of future minimum lease payments
2,016	$ 266,800
2,017	357,800
2,018	336,700
2,019	335,100
2,020	347,300
Thereafter	909,800
Total	$ 2,553,500

Commitments and Contingencies53

Commitments and Contingencies (Details Textual)	Dec. 31, 2007USD ($)Installments	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)Office	Dec. 31, 2013USD ($)
Operating Leased Assets [Line Items]
Research and development contracts			$ 3,985,000
Research and development contracts description			Through March 31, 2016
Letter of credit			$ 390,800
October 2018 [Member]
Operating Leased Assets [Line Items]
Letter of credit decrease amount			234,400
October 2022 [Member]
Operating Leased Assets [Line Items]
Letter of credit decrease amount			$ 156,000
Medeor [Member]
Operating Leased Assets [Line Items]
Royalty payments description			(A) royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product.
Royalty received by licensee description			(i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 million and up to $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively.
Licensing Agreements [Member]
Operating Leased Assets [Line Items]
Number of licensed products | Installments	2
License fees received	$ 1,500,000
Royalties description	License fee of $1,500,000 and will earn royalties of up to 12% of net sales for up to two licensed products it is currently developing.
Licensing Agreements [Member] | Minimum [Member]
Operating Leased Assets [Line Items]
License expiry term	15 years
Licensing Agreements [Member] | Maximum [Member]
Operating Leased Assets [Line Items]
License expiry term	20 years
Lease Agreements [Member]
Operating Leased Assets [Line Items]
Rent expense		$ 13,300	$ 239,800	$ 67,800
Description of lease expiration date			The lease expires in December 2023. In addition, the Company has a lease expiring in 2017 for its Pennsylvania office location.
Number of corporate office | Office			2

Transition Period Comparable 54

Transition Period Comparable Information (Unaudited) (Details) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2013
Operating expenses:
Research and development	$ 839,959		$ 7,872,397		$ 5,248,669
General and administrative	12,106,859		9,226,883		1,525,257
Total operating expenses	12,946,818		17,099,280		6,773,926
Loss from operations	(12,946,818)		(17,099,280)		(6,773,926)
Other (expenses) income:
Loss on change in fair value of derivative liabilities	(7,954,970)		(3,710,277)		$ (12,877,675)
Interest income	1,411		10,883
Interest expense	435,611		4,922		$ 220,307
Total other expenses	(8,389,170)		(3,704,316)		(13,097,982)
Net loss	$ (21,335,988)		$ (20,803,596)		$ (19,871,908)
Net loss per common share
- basic and diluted	$ (8.65)		$ (2.09)		$ (40.90)
Weighted average common shares outstanding
- basic and diluted	2,466,466		9,941,156		485,853
Parent Company [Member]
Operating expenses:
Research and development	$ (839,959)	$ (708,551)	$ (7,872,397)	$ (5,380,077)
General and administrative	(12,106,859)	(528,352)	(9,226,883)	(13,103,764)
Total operating expenses	$ (12,946,818)	$ (1,236,903)	$ (17,099,280)	$ (18,483,841)
Loss from operations
Other (expenses) income:
Loss on change in fair value of derivative liabilities	$ (7,954,970)	$ (11,861,302)	$ (3,710,277)	$ (8,971,343)
Interest income	1,411		10,883	1,411
Interest expense	(435,611)	$ (41,667)	(4,922)	(614,251)
Total other expenses	(8,389,170)	(11,902,969)	(3,704,316)	(9,584,183)
Net loss	$ (21,335,988)	$ (13,139,872)	$ (20,803,596)	$ (28,068,024)
Net loss per common share
- basic and diluted	$ (8.65)	$ (27.35)	$ (2.09)	$ (18.89)
Weighted average common shares outstanding
- basic and diluted	2,466,466	480,477	9,941,156	1,486,126

Transition Period Comparable 55

Transition Period Comparable Information (Unaudited) (Details 1) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2013
Net cash used in operations	$ (2,164,254)		$ (16,226,728)		$ (2,237,529)
Net cash used in investing activities	(3,673)		(23,326)		(8,871)
Net cash provided by financing activities	24,209,828		13,155,663		$ 3,996,028
Parent Company [Member]
Net cash used in operations	(2,164,254)	$ (992,190)	(16,226,728)	$ (7,213,709)
Net cash used in investing activities	(3,673)		(23,326)	(11,740)
Net cash provided by financing activities	24,209,828	$ 779,096	13,155,663	31,230,072
Increase (decrease) in cash and cash equivalents	$ 22,041,901	$ (213,094)	$ (3,094,391)	$ 24,004,623

Subsequent Events (Details)

Subsequent Events (Details)	12 Months Ended
	Jun. 30, 2015shares
Subsequent Event [Member]
Subsequent Events (Textuals)
Common stock issued from exercise of warrants	36,439
Issuance of shares for services, Shares	7,500
Warrants [Member]
Subsequent Events (Textuals)
Number of Shares, exercisable	2,033,915
Warrants [Member] | Subsequent Event [Member]
Subsequent Events (Textuals)
Number of Shares, exercisable	28,939